DEVELOPMENT AND CHARACTERIZATION OF NANOMATERIALS FOR PULMONARY DRUG DELIVERY APPLICATIONS by Torrico Guzman, Elisa A.
University of Rhode Island 
DigitalCommons@URI 
Open Access Dissertations 
2019 
DEVELOPMENT AND CHARACTERIZATION OF NANOMATERIALS 
FOR PULMONARY DRUG DELIVERY APPLICATIONS 
Elisa A. Torrico Guzman 
University of Rhode Island, torrico.elisa@gmail.com 
Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss 
Recommended Citation 
Torrico Guzman, Elisa A., "DEVELOPMENT AND CHARACTERIZATION OF NANOMATERIALS FOR 
PULMONARY DRUG DELIVERY APPLICATIONS" (2019). Open Access Dissertations. Paper 864. 
https://digitalcommons.uri.edu/oa_diss/864 
This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for 
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more 
information, please contact digitalcommons@etal.uri.edu. 
  
DEVELOPMENT AND CHARACTERIZATION OF NANOMATERIALS FOR 
PULMONARY DRUG DELIVERY APPLICATIONS 
 
BY 





A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
































Major Professor   Samantha A. Meenach 
 
        Geoffrey Bothun 
 
        Sara Rosenbaum 
 
   Nasser H. Zawia 














Chronic pulmonary diseases such as lung cancer and cystic fibrosis represent 
significant global health concerns because of their resulting high mortality and low life 
expectancy. Pulmonary drug delivery has demonstrated advantages over other delivery 
routes due to the ability to use lower concentrations of drug, reduction in systemic 
toxicity, and offering better targeting to the area of disease. Effective application of dry 
powder therapeutics requires the optimization of particle deposition in the lungs and 
avoidance of physiologic defense mechanisms such as mucosal entrapment, mucociliary 
clearance, and macrophage engulfment. Evaluation of aerosol pulmonary therapeutic 
parameters demands accurate in vitro models that can appropriately simulate the 
pulmonary environment, such that the results can accurately translate to in vivo testing. 
In addition, there is a need in the development of nanoparticle-based therapeutics 
capable of delivering chemopreventive agents owing to their poor water solubility and 
large concentration requirements for efficacy.  
This dissertation was aimed at: (i) developing and evaluating resveratrol-loaded 
nanoparticles capable of preventing in vitro tumors spheroid growth, (ii) developing and 
characterizing dry powder paclitaxel-loaded nanocomposite microparticles, and 
evaluating their efficacy in the growth inhibition of lung cancer tumor spheroids using 
an in vitro three-dimensional air interface culture model, and (iii) developing and 
characterizing PEGylated nanocomposite microparticles, and evaluating their ability to 




Biodegradable nanoparticles were formulated with appropriate size for cellular 
uptake (~200 nm). The nanoparticles demonstrated tunable, pH-dependent sustained 
release for up to 4 days using 3-hour acetalated dextran. The nanoparticles showed 
increased colloidal stability with hydrophobic therapeutic agents and improved mucus-
penetrating capabilities when coated with vitamin E poly(ethylene glycol) (VP5k). 
Nanoparticles loaded with resveratrol, a natural chemopreventive agent, showed 
superior inhibition of tumor growth when dosed in comparison to free resveratrol. 
Finally, nanocomposite nanoparticles loaded with paclitaxel (PTX), a toxic 
chemotherapeutic agent, showed comparable efficacy in comparison to free PTX. 
Spray-dried nanocomposite microparticles demonstrated excellent aerosol 
performance when evaluated with an in vitro Next Generation Impactor for dry powder 
inhaler formulations, with a tunable targeted deposition depending on the formulation 
and spray drying conditions. These results highlight multiple beneficial characteristics 
of inhaled drug delivery with nanocomposite microparticles for lung cancer treatment, 
including sustained release over a long period of time, tunable deposition to the desired 
area within the bronchopulmonary tract, and improved mucus penetration. Additionally, 
the results observed in our 3D cell culture models differed from those observed in a 2D 
monolayer of cells, demonstrating the importance of accurate in vitro models to allow 
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This dissertation is presented in manuscript format in accordance with The 
University of Rhode Island Graduate School Guidelines and is comprised of six 
chapters. The first chapter is an introduction and overview of the dissertation, which 
includes the objectives and significance of the work. The second chapter, entitled 
“Pulmonary Delivery of Nanocarriers” involves in part a review of literature in 
contribution to the book chapter entitled “Routes of Administration for Nanocarriers” 
submitted as chapter 6 in the book Nanoparticles for Biomedical Applications (Elsevier 
S&T Books). The third chapter, entitled “Evaluation of the Cancer-Preventive Effect of 
Resveratrol-Loaded Nanoparticles on the Formation of Lung Tumor Spheroids” is a 
manuscript in preparation for the submission to the journal Nanomedicine: 
Nanotechnology, Biology, and Medicine. The fourth chapter, entitled “Development and 
Evaluation of Paclitaxel-Loaded Aerosol Nanocomposite Microparticles and Their 
Efficacy Against Lung Cancer Tumor Spheroids” is a manuscript in preparation to 
submit to Journal of Biomedical Nanotechnology. The fifth chapter, entitled 
“Development and Characterization of Aerosol Nanocomposite Microparticles Capable 
of Mucus Penetration” is being prepared for submission to the journal Colloids and 
Surfaces B: Biointerfaces. The sixth chapter is a summary of the main conclusions of 
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1.1.  Overview and Motivation 
Lung cancer is the leading cause of cancer-related deaths in the United States, 
representing more than one-quarter of all cancer deaths. The five-year relative survival 
rate is 54% for localized tumors, 26% for regional cancers, and 4% for distant 
metastases, resulting in a combined 19% survival rate when all stages are considered, 
causing about 390 deaths per day in the U.S. [1]. Despite the advances in cancer 
treatment over the past 40 years, the survival rates for lung cancer patients still remains 
devastatingly low. The types of lung cancer can be separated into two major groups: 
small cell lung cancer and non-small cell lung cancer (NSCLC). The work described in 
this dissertation focuses on NSCLC, as this represents 80-85% of lung cancer diagnoses 
[2]. 
Monolayer 2D cell culture has been used to evaluate the efficacy of anti-cancer 
therapeutics for many years; however, the resulting information has limitations when 
translated to in vivo studies. 3D cell culture models provide a more accurate 
representation of the properties of tumors with respect to morphology, response to 
therapeutics, growth kinetics, presence of a necrotic core, and diffusion limitations [3]. 
These characteristics make the inner core of tumors less accessible to therapeutics, 
shielding their potential impact on that region of tumor cells, an effect that is not well 
demonstrated in 2D models. As a result of this effect, therapeutics are only able to attack 
the surface cells of tumors, which may quickly replenish if the tumor core is not also 
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eliminated [4, 5].  2D cell assays cannot replicate many properties of 3D models such 
as the intercellular interactions found in vivo [6]. The use of 3D multicellular spheroids 
is advantageous in testing drug efficacy because they more accurately mimic tumor 
tissue. 
Pulmonary delivery of therapeutics has been extensively studied as a promising 
route for the targeted delivery of compounds to the lungs. Traditionally, this therapy has 
been used for the treatment of asthma and chronic obstructive pulmonary disease 
(COPD) [7], and involves the use of aerosol devices. In recent years, pulmonary drug 
delivery applications have expanded in the treatment of other local diseases such as lung 
cancer and cystic fibrosis (CF) [8], and furthermore to the treatment of diseases such as 
diabetes through systemic delivery of drugs following inhalation. The advantages of 
using aerosol treatment include better targeting to the lungs and reduced systemic side 
effects seen with high drug doses in the body [9]. 
Successful pulmonary delivery is determined by the effective deposition of 
particles in specific regions in the lungs, and in the overcoming of clearance 
mechanisms inherent to the respiratory tract [10]. The optimal aerodynamic diameter 
required for particles to deposit in the distal region of the lungs is 1 to 5 µm [11]. 
Particles smaller than 1 µm may be easily exhaled, while those larger than 5 - 50 µm 
may become trapped in the upper airways (nose, mouth or larynx). Furthermore, 
microparticles in the 1 to 5 µm range can be phagocytosed by alveolar macrophages 
[12]. Nanoparticles usually have a size range of 1 to 500 nm [13], which allows them to 
penetrate physiological barriers and affords them greater overall surface area; they can 
also enhance the dissolution rates and bioavailability of encapsulated drugs, reasons 
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why there are extensively studied in drug delivery [14]. Unfortunately, nanoparticles 
are extremely light to be used alone in dry powder inhalers, as they will mostly be 
exhaled instead of depositing on lung tissue.  Table 1.1 shows summarize of advantages 
and limitation of the use of nanoparticles and microparticles in pulmonary delivery.  
 
Table 1.1 Advantages and limitations of nanoparticles and microparticles in pulmonary 
delivery. 
Particle Type Pros Cons 
Nanoparticles Can penetrate 
physiological barriers; 
larger surface area 
Too small to deposit in 
lungs (too light) 
Microparticles Can deposit effectively in 
lungs 




As an alternative, nanoparticles can be encapsulated in a larger microparticle 
carrier, resulting in a dry powder nanocomposite microparticle (nCmP) system, that can 
take advantage of both microparticle and nanoparticle characteristics for effective 
pulmonary delivery of dry powders [15] (Figure 1.1). nCmP can effectively be 
delivered to the lungs owing to their micron size and will then dissociated into 
nanoparticles that have the potential to avoid macrophage clearance and/or penetrate 
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physiological barriers. nCmP can be synthesized via the spray drying of a suspension 
containing drug-loaded nanoparticles and a water dispersant carrier or excipient. 
Carriers commonly used are sugars (lactose, trehalose, sucrose), sugar alcohols 
(mannitol, xylitol), and cyclodextrins, which allow for the recovery of nanoparticles 




Figure 1.1  Schematic of Paclitaxel nCmP delivery via inhalation. 
 
Aside from the need to deposit at the site of a particular disease state, pulmonary-
based therapeutics encounter a variety of physiological barriers, such as mucus, which 
selectively traps large particles and removes them via mucociliary clearance [17]. 
Multiple strategies have been studied for overcoming the mucosal layer in the lungs, 






1.2.  Objectives and significance 
The overall purpose of this dissertation was to develop and characterize 
nanoparticles and nanocomposite microparticles formulations for a variety of drug 
delivery applications, followed by their evaluation in cell culture platforms that can 
more accurately represent lung environments for pulmonary delivery applications. The 
projects of this dissertation and their significance are outlined as follows: 
 
Project 1.  Evaluation of the cancer-preventive effect of resveratrol-loaded 
nanoparticles on the formation of lung tumor spheroids 
Previous studies have characterized the potential chemopreventive properties of 
resveratrol (RSV) in cancer cells [20, 21]. Traditionally, these studies have relied on the 
treatment of cancer cells in 2D cell culture. The purpose of this project was to evaluate 
the ability of RSV-loaded nanoparticles to prevent the formation of tumor spheroids in 
a 3D cell culture environment (Figure 1). Previous studies on the role RSV plays in 
chemoprevention for lung cancer is very limited and this project aimed to provide 




Figure 1.2  Schematic of (Left) the formation of multicellular tumor spheroids (MCS) 
in ultra-low attachment 96-well plates via centrifugation and (Right) morphology of 
solid tumors. 
 
Project 2. Development and Evaluation of Paclitaxel-Loaded Aerosol 
Nanocomposite Microparticles and Their Efficacy Against Lung Cancer Tumor 
Spheroids 
Current treatments for lung cancer carry adverse effects due to the large amounts 
of drug delivered intravenously throughout the body, with poor local delivery and 
detrimental effects on otherwise healthy tissue. In this study this challenge was 
confronted via the development of paclitaxel-loaded nanocomposite microparticles 
(nCmP) as pulmonary drug delivery-related dry powder particles delivered via a dry 
powder inhaler system. nCmP have the potential to effectively deposit in the lower parts 
of the lungs, release the drug-loaded nanoparticles at the site of the disease in a 
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controlled manner, and escape macrophage engulfment due to their nano-scale size. 
This system could allow for the administration of lower amounts of drug by delivering 
it directly to the tumor site, consequently reducing the toxicity and inherent side effects 
of conventional I.V. chemotherapy.  
Recently, 3D models have been developed for a variety of lung cancer cell types 
in liquid covered culture (LCC), however, this is not representative of what takes place 
in the airways of the lungs, where aerosol anti-cancer therapeutics will be delivered. In 
this project, once the spheroids were formed they were grown in air interface culture 
(AIC) conditions to better represent tumor formation in the lungs. Following spheroid 
formation and characterization, the efficacy of different aerosol anticancer therapeutics 
was evaluated on this platforming in order to enhance the predictable transition from 




Figure 1.3  Schematic of (Top) the fabrication of the alginate hydrogel scaffold and 
(Bottom) formation of 3D multicellular spheroid (MCS) in an air interface cell culture 
(AIC) for the evaluation of Paclitaxel nCmP. 
 
Project 3. Development and characterization of aerosol nanocomposite 
microparticles capable of mucus penetration  
Mucus is a very efficient barrier that prevents the penetration of harmful agents and 
pathogens to the underlaying tissue in the lungs, and is thus a challenge for effective 
pulmonary drug delivery [18]. Overcoming this barrier will allow effective permeation 
into mucus and escape of the mucosa removal of therapeutics so that they can reach the 
site of infection seen in diseases such as cystic fibrosis, in which patients are faced with 
thick mucus and continuous infections in the lungs. Also, chronic diseases such as lung 
cancer, located in the epithelium underneath the mucosa layer, are faced with this 
mucosal barrier. Finally, mucus and surfactant cover the entirety of the pulmonary tract 
and having a therapeutic that can reach the alveoli region and penetrate the mucus or 
surfactant layer may allow the systemic delivery of encapsulated dugs after inhalation. 
Thus, this project involved the development and evaluation of nanocomposite 
microparticle (nCmP) containing nanoparticles PEGylated with vitamin E 
poly(ethylene glycol) (VP5k). The nCmP were able to aerosolize and demonstrated 
aerodynamic diameters necessary for delivery into several regions of the lungs and the 
dissociated nanoparticles were able to effectively penetrate artificial mucus better than 
poly(vinyl alcohol)-coated nanoparticles. Overall, this aerosol microparticle system has 
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the potential to delivery therapeutics to the lungs and effectively penetrate the mucosal 
barriers present there. 
 
Figure 1.4  Schematic of the mucus penetrating properties of vitamin E poly(ethylene 
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Pulmonary Delivery of Nanocarriers 
 
2.1.  Introduction 
In the recent years, pulmonary delivery has attracted growing interest in the 
research community for its advantages over other delivery systems to treat local diseases 
in the lungs and respiratory tract such as asthma and chronic obstructive pulmonary 
diseases (COPD) [1] as well as systemic delivery of biotherapeutics through pulmonary 
route (i.e. peptides and proteins) [2]. The local treatment of pulmonary diseases provides 
high concentration of a drug at the site by directly delivery to the lung. As a result, lower 
overall dose is required, thus reducing the systemic side effects. Due to the high surface 
area in the lungs, a systemic delivery can be attained in the alveoli, where the API is 
absorbed into the blood stream; therefore, a rapid onset of action can be achieved, and 
the first-pass metabolism avoided. 
 
2.2.  Lung Physiology  
Internally, the lungs are divided into bronchi, bronchioles and smaller air 
passages: alveoli, blood vessels and lymph tissue. The main function of the lungs is to 
exchange oxygen and carbon dioxide. The gas exchange occurs in the alveoli. There are 
over 300 million alveoli in the lungs, with a combined surface area of about 100 m2, 
thin alveolar epithelium (0.1 – 0.2 µm), and high membrane permeability, which enables 
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an efficient mass transfer providing a route for systemic delivery [3, 4] The alveolar 
surface is coated by a film of pulmonary surfactant, a complex of lipids and proteins. 
The lipid fraction is mainly composed by phospholipids, 
dipalmitoylphosphatidylcholine (DPPC), phosphatidylglycerol, and some neutral lipids. 
The surfactant is secreted and recycled by type II pneumocytes and cleared by alveolar 
macrophages [5] The surfactant reduces the surface tension by stabilizing the interface 
during the inspiration-expiration process and represents the first barrier against 
pathogens [6]. From the large bronchioles up to the trachea, the epithelium of the 
airways is covered by mucus, produced by goblet cells. The bronchi tree surface 
contains ciliated columnar cells which is responsible for mucociliary clearance, Clara 
cells that produce electron-dense granules, and a surfactant lipoprotein that intervenes 
in the ion transport [5].  
 
2.3.  Delivery Devices 
The three major types of inhalers used for pulmonary delivery are: Metered dose 
inhalers (MDIs), Nebulizers, and dry powder inhalers (DPIs). The mechanisms of 
delivery and the formulation requirements are different for each type. 
 
2.3.1.  Metered dose inhalers (MDIs) 
The first metered dose inhaler (MDI) was developed in 1950s to locally deliver 
albuterol for the treatment of asthma [7]. MDIs are pressurized vessels that rely on the 
driving force of the propellant to atomize the droplets containing the drug and 
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excipients, which ideally deposit in the lungs [8]. The main components of MDI device 
are the propellant, formulation, metering valve and actuator. All of them play an 
important role in the formation of spray and determine the drug delivery into the lungs. 
The main component of the propellant has been formulated with high volatile FCF-12 
(dichlorodifluoromethane). Drugs are either solutions or particulate suspensions. The 
formulations usually contain surfactants that may impact the lung performance. An 
optimal drug deposition in the lungs using MDIs requires coordination between 
actuation and inhalation, which makes it more difficult to use for patients [4, 8]. 
 
2.3.2.  Nebulizers 
Nebulizers deliver liquid medication in a steady stream of droplets of 1-5 µm 
and do not require patient coordination between inhalation and actuation, which is 
advantageous for the use in infants, elderly or non-conscious patients. Nebulizers can 
deliver larger doses compared to other inhalers, but may also require longer times [9]. 
Nebulizers produce ultra-fine droplets (~1µm) with high polydispersity, which make 
them unsuitable for the delivery of larger particles (bigger than the droplet size) to the 
lungs [10]. In jet nebulizers, a high velocity of air carries the droplets and impacts on 
baffles to break them into smaller sized droplets or to retain them until they reach the 
appropriate size. In ultrasonic nebulizers, the vibration of piezoelectric crystals at high 
frequency creates waves that break the liquid into small droplets [9]. The aerosol drug 
delivery via nebulizers is influenced by the type, the position on the ventilator circuit 
and the bias flow as was reported by Ari et al. during a study on simulated pediatric and 
adult lung models during mechanical ventilation [11].  
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2.3.3.  Dry Powder Inhaler (DPI) 
DPIs are breath-activated devices that deliver medication in the form of a dry 
powder directly to the airways. During administration, the capsule containing a set dose 
of drug in the form of microparticles is punctured and the internal particles are 
aerosolized. [12]. DPIs are breath-activated requiring no outside energy source or 
propellant. In addition, no coordination between patient inhalation and activation of the 
device is needed.  The inspiration flow can be as little as 30 LPM for devices such as 
Diskus, or 60 LPM or more for devices with higher resistance like Handihaler [13]. The 
optimal drug delivery requires a deep, forceful and long inhalation for at least 5 seconds, 
followed by a breath hold for at least 10 seconds [14]. However, in the case of acute 
asthma attacks, DPIs are not recommended because of the inspiratory flow requirement 
[15]. The actual dose delivered is also dependent on the inhalation flow, which can be 
difficult to replicate. Furthermore, particles delivered using DPIs tend to agglomerate 
due to hygroscopic phenomena and electrostatic interactions, which reduce the 
aerosolization performance [4]. Overall, DPIs are preferred over other devices because 
it promises physical stability of the formulation in solid form, is portable and easy to 
use, and can be applied to a wide variety of active ingredients and dose weights [10, 
16]. There are two main types of DPIs: single-dose and multi-dose inhalers. Single-dose 
DPIs supply an individual capsule per dose, while the multidose DPIs contain a bulk 




2.4.  Particle Fate 
Particle deposition in the lungs is governed by the aerodynamic diameter of the 
particles and occurs by one of the following mechanisms: inertial impaction, 
sedimentation, or diffusion. Nanoparticles deposit by diffusion are caused by Brownian 
motion, and can be enhanced by breath holding (reduction of airflow). Aggregates of 
nanoparticles at a micro-size scale (i.e. nanocomposite microparticles) are thought to 
have enough mass to deposit effectively into the lungs and respond to impaction and 
sedimentation mechanisms. Once the micro-sized particles deposit in the airways, they 
dissociate back into nanoparticles [17, 18]. Inhalable particles can be categorized into 
different sizes either coarse (≥ 5 µm), fine (0.5–5 µm), or ultrafine (≤ 0.5 µm). Figure 
2.1 shows the percent of deposition based on the aerodynamic diameter of particles [19].  
 
 




Coarse carriers collide with the upper airways (trachea and large bronchi) and 
deposit by impaction; fine particles can reach the lower lung airways by sedimentation, 
and ultrafine particles can deposit  throughout the respiratory tract, reaching the alveoli 
by diffusion, but also can be exhaled for being very light [3]. Table 2.1 summarizes the 
different mechanism of deposition in the respiratory tract. 
 
  Table 2.1 Mechanisms of aerosol deposition [3, 20] 
Mechanism Size Site of deposition Cause 
Impaction ≥ 5 µm 
Upper respiratory 
airways – Primary 
bronchi 
Airflow is turbulent 
and air velocity is 
high 






residence time of 
carrier travel 
through the airway 
increases 
 
Diffusion < 0.5 µm Alveoli 
Brownian motion - 
random motion due 
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to the bombardment 
by surrounding air 
molecules. 
 
Another parameter that can influence the particle deposition in the respiratory 
tract is the electrostatic charge that occurs in most of the inhalers during the 
aerosolization process. Fine particles can acquire charge via electron exchange due to 
the different surface potential when they are in contact to each other or to the walls of 
the device [21]. The electrostatic effects are more pronounced in the upper airways 
before the charge is dissipated due to high humidity [22], and can cause an increase of 
the overall percentage deposition up to sevenfold [23]. This effect may be not be desired 
for systemic delivery of the drugs, which requires particles to reach the alveolar 
epithelium [24]. NP in epithelial cells are uptaken by endocytotic mechanisms, which 
involves pinocytosis or uptake of fluids and molecules in small vesicles, and 
phagocytosis, which is responsible for engulfment of large particles such as 
microorganism or cells debris [25]. The clearance mechanism of particles depends on 
the location of the deposited agent. In the upper airways, particles are removed by the 
mucociliary escalator that is comprised by hair-shaped structure cilia, located on the 
topside of epithelial cells. Once mucus entraps foreign particles, cilia beat in a 
coordinated direction and transport them to the larynx where the particles can be 
coughed up or swallowed. Most insoluble particles larger than 6 µm in aerodynamic 
diameter are eliminated by mucociliary clearance [26]. Smaller particles that reached 
the alveoli are uptaken by alveolar macrophages, that detect foreign agents, and engulf 
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them via phagocytosis. Phagocytic uptake is the main mechanism to remove 
microorganism, cells debris or insoluble micro-sized particles from the lungs surface 
when they have escaped from other clearance mechanisms [27]. Most of the 
nanoparticles migrate with the load into the bronchioles to reach the mucociliary 
escalator current, and others migrate through the epithelium into the lymphatics [5]. In 
general, nanoparticle clearance and uptake will be also affected by other parameters 
such as API’s properties, type of nanoparticle, size and surface coating, and interaction 
of NP with cells. The cellular and non-cellular barriers that nanocarriers may face can 
be seen in Figure 2.2. 
 
 
Figure 2.2  Cellular and non-cellular pulmonary barriers for nanocarriers including 
those present in the central lung/upper airways (bronchial) and peripheral/lower airways 




2.5.  Applications 
Inhalation therapy of nanomedicines enables the delivery of small molecule 
drugs within the lungs for the treatment of local pulmonary diseases such as lung cancer 
[29], cystic fibrosis related infections [30], and pulmonary hypertension [31] among 
others. The pulmonary delivery of peptide and proteins represents a great potential for 
the treatment for both local and systemic diseases such as diabetes and thrombosis. Gene 
delivery [32] and vaccines are other applications of pulmonary inhalation. Examples of 
drugs using colloidal carriers such as lipids, solid lipid nanoparticles and polymeric 
nanoparticles for diverse applications are reviewed elsewhere [33]. Pulmonary delivery 
was also applied for diagnostic purposes where iodinated nanoparticles were instilled 
into small airways and were transported to the tracheobronchial lymph nodes in dogs. 
The study resulted in contrast enhancement confirmed by computed tomography 2-3 
days later [34]. In a recent study, liposomes functionalized with phosphatidic acid and 
an ApoE-derived peptide (mApoE-PA-LIP) were delivered to the brain of Alzheimer’s 
disease mice via the pulmonary administration, showing a significant decrease in the 
total brain beta-amiloyd compared to untreated mice, and suggesting a potential 
application of inhalation therapy for brain delivery of NP [35]. Several studies are 
ongoing applying pulmonary delivery for different drugs/agents using different carriers. 





Table 2.2 Sample nanocarrier formulations based on route of delivery, nanocarrier type, 
disease and/or application, and development state, where PLGA = poly(lactic-co-
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Diabetes 









Magnetic Fe3O4 in 
PLGA NP 
Quercetin; lung cancer 
and imaging 












In vitro [39] 
 
2.6.  Challenges, Advantages, and Limitations 
Pulmonary route offers the advantage of the delivery of poor water soluble 
compounds that cannot be achieved by parenteral or oral delivery [3]. Because the lung 
presents limited intracellular and extracellular drug-enzyme activities, the 
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bioavailability of the drug can be enhanced compared with in the gastrointestinal tract 
or liver. Correspondingly, doses that need to be administered can be reduced leading to 
a decreased systemic toxicity [40]. The higher adsorption rate and the rapid onset of 
action are due to the thin monolayer (0.1 – 0.4 µm) and large surface area (more than 
100 m2) in the alveoli [20], which represent a route for systemic delivery. Small peptides 
may suffer enzymatic degradation in the lungs, however in a lower intensity than in the 
gastrointestinal tract. Proteins greater than 150 kDa have a reduced transport and 
therefore, more difficulty to reach the systemic circulation. Despite the challenges, 
pulmonary delivery represents a potential route to deliver peptides and small proteins 
beyond the lungs [4]. Parameters to consider to ensure an effective targeting into the 
lungs include: (i) deposition and localization of drugs in the targeted area or cells, (ii) 
ability to escape from mucocliary clearance, (iii) penetration through mucus in the 
airways, (iv) transport across epithelial cells to reach the blood stream for systemic 
delivery, (v) low entrapment and interaction of drugs by bacteria biofilms in case of 
infections, (vi)modified or reduced phagocytic activity by alveolar macrophages, and  
(vii) minimal host protein- drug interaction to reduce enzymatic degradation [26]. In 
order to address the challenges, it is important to focus on both the physicochemical 
properties of the NP such as surface chemistry/charge, hydrophilicity, and the 
pulmonary barriers such as cilia, mucus and macrophages that limit the localization, 
penetration and adsorption of carriers in the lungs [41].  
Interactions between NP and cells are of particular interest because the 
properties of the carriers as well as the physiological environment influence nanocarrier 
uptake and biological response to the delivered drug [25]. Cationic hydrogel rod-shaped 
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NP resulted in increased uptake in lung dendritic cells and promoted a superior immune 
response, avoiding extensive alveolar microphages (AM) clearance, while the anionic 
counterpart NP were preferentially uptaken by AMs and immunologically inert [42]. In 
another study, while cationic PS NP still showed faster and higher uptake in alveolar 
epithelial model cells, anionic PS NP had a significant uptake and translocation through 
the monolayer for systemic delivery application [43].  
Pegylated polyaspartamide-polylactide-based NP demonstrated the ability to 
enhance the diffusion through cystic fibrosis artificial mucus avoiding interactions with 
mucus components compared to unPEGylated NP [87]. The limited number of FDA-
approved excipients for inhalation, which include sugars, lipids, and small PEGs, among 
others, represent a limitation in the development of new formulations for pulmonary 
delivery and use of new excipients will require further safety and toxicity studies studies 
[44]. Additives for pulmonary administration also influence the effectiveness and 
potential toxicity of inhalation formulations, which has been reviewed in Pilcer and 
Amighi’s work [45]. 
 
2.7.  Potential applications 
The challenges involved in effective pulmonary delivery has resulted in strong 
interest in developing formulations that can overcome physiological and biological 
barriers. Studies involving nanocarriers that allow for mucus penetration include the 
surface modification with PEG-based coatings, reviewed by Huckaby et al.[46]. The 
potential use of other mucus-inert biomaterials such as polysarcosine, polyglycydol, etc 
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and mucolytic agents such as papain and human DNase (rhDNase), among others, have 
been reviewed elsewhere [47, 48]. Other surface modifications for the enhancement of 
peptide or protein absorption are of great interest, as evaluated in the conjugation of 
liposomes to germ agglutinin that increased the association of liposomes to alveolar 
epithelial cells in vitro and in vivo [49]. The carrier interactions with biological barriers 
and in vitro pulmonary models for more accurate evaluations represent fields under 
exploration, as seen in the review by de Souza Carvalho et al. [28]. Overall, the potential 
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ABSTRACT 
Resveratrol (RSV) is a natural polyphenol with antioxidant, anti-inflammatory, 
and chemopreventive benefits. This project evaluated the ability of RSV-loaded 
nanoparticles (NP) to prevent the growth of and to treat lung tumor spheroids in vitro. 
RSV was encapsulated in NP comprised of a biodegradable polymer, acetalated dextran 
via single emulsion and solvent evaporation. Free RSV and RSV NP were tested in two-
dimensional and three-dimensional cell culture models to evaluate their effects on A549 
lung cancer cells and tumor spheroids. RSV NP were evaluated on spheroids for 
prevention, dosing at day 0, and for treatment, dosing on fully formed spheroids. Results 
showed that the RSV NP were 200 nm in size with neutral charge, exerted a greater 
inhibitory effect on viability and growth of cancer cells and spheroids in comparison to 
free RSV, demonstrating their potential as a chemopreventive agent for both prevention 
and treatment applications.  
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3.1.  Introduction 
Despite advancements in the treatment of cancer, this disease remains an 
enormous challenge for scientists. It is estimated that 1,762,450 new cases of cancer 
will be diagnosed in the U.S. in 2019 and that there will be 606,880 cancer-related 
deaths, which corresponds to over 1,662 deaths per day. Among all cancers, lung and 
                                               
1 RSV = resveratrol; NP = nanoparticles; Ac-Dex = acetalated dextran; CUR = 
curcumin; CAC = cyclic acetal coverage; 2D = two-dimensional; 3D = three-
dimensional; MCS = multicellular tumor spheroids; PPTS = pyridinium p-
toluenesulfonate; DMSO = dimethyl sulfoxide; 2-MOP = 2-methoxypropene; TEA = 
triethylamine; DCM = dichloromethane; PVA = polyvinyl alcohol; PBS = phosphate 
buffered saline; NMR = nuclear magnetic resonance; DLS = dynamic light scattering; 
PDI = polydispersity index; DL = drug loading; EE = encapsulation efficacy; UPLC = 
ultra-performance liquid chromatography; DMEM = Dulbecco’s modified Eagle’s 
medium; FBS = fetal bovine serum; AP = acid phosphatase; pNPP = p-nitrophenyl 
phosphate; DNA = deoxyribonucleic acid; DAPI = 4′,6-diamidino-2-phenylindole; GFP 
= green fluorescent protein. 
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bronchus cancers have the highest mortality rates and resulted in an estimated of 
142,670 deaths in 2019 [1].  
Chemotherapy is one of the mainstays of lung cancer treatment, however its 
efficacy is often limited. An emerging field in the treatment of cancer has been the use 
of chemopreventive phytochemicals, which are constituents of fruits and vegetables 
with potential pharmacological and/or nutritional functions in preventing oncogenesis. 
These agents may reverse or inhibit the carcinogenic process at a cellular level, resulting 
in decreased cancer risk [2, 3]. The Food and Drug Administration (FDA) has approved 
several chemopreventive agents, including: tamoxifen [4-6] and raloxifene for breast 
cancer risk reduction [7]; celecoxib, which may reduce colorectal adenomas in familial 
adenomatous polyposis [8]; and the human papillomavirus vaccine [9]. More than 200 
other chemopreventive agents are currently in clinical trials [10]. Landis-Piwowar et al. 
have listed dietary phytochemicals and synthetic chemopreventive compounds, 
indicating their potential effects [11]. Some phytochemicals act as blocking agents to 
prevent DNA mutations, such as turmeric and green tea, and others block molecular 
pathways leading metastasis (e.g. curcumin and gingerol). A number of clinical trials 
have evaluated vitamin A [11, 12] , vitamin E, aspirin, selenium, and others as potential 
chemopreventive agents for lung cancer, however, none have shown a clear positive 
benefit [13]. Other compounds (glucocorticoids, myoinositol) showed potential benefits 
in preclinical models, but further studies are required to establish their efficacy [14]. 
Overall, there is no formulation available for the prevention of lung tumor formation.  
Resveratrol (3,5,4′-trihydroxy-trans-stilbene, RSV) is a phytoalexin [15] that is 
abundantly found in red grapes, as well as in peanuts and blueberries. In 1997, interest 
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in RSV increased when Jung et al. reported its chemopreventive effects in all stages of 
neoplastic activity (initiation, promotion and progression) [16]. A later study by Dolfini 
et al. showed that RSV induces drastic growth inhibition on a human breast cancer cell 
line in both in vivo and in vitro assays [17].  
Although RSV has shown great potential as a chemopreventive drug, it exhibits 
poor water solubility, resulting in limited bioavailability [18, 19]. Approaches to 
increasing the solubility of RSV have included using surfactants and cyclodextrins in 
formulations [20, 21], however nanotechnology has been extensively explored to 
encapsulate and deliver hydrophobic compounds, thus increasing therapeutic 
bioavailability [22-24]. RSV-loaded gel nanoparticles demonstrated improved 
intracellular uptake and cytotoxicity in NCI-H460 lung cancer cells in comparison to 
free RSV [25], while RSV loaded into nanostructure lipid carriers exhibited higher 
penetration into the skin in comparison to solid lipid nanoparticles [26]. Both studies 
highlight the improvement of RSV efficacy in nanoparticle formulations compared to 
their free form in vitro. Furthermore, animal studies showed that RSV solid lipid 
nanoparticles enhanced the bioavailability of RSV in the brain when delivered to rats 
for vascular dementia [27]. 
For this project we synthesized the biodegradable, biocompatible, acid-
responsive, and tunable polymer acetalated dextran (Ac-Dex) [28] to encapsulate RSV. 
The facile degradation of Ac-Dex in acidic conditions makes it suitable for the release 
of compounds to cancer cells that develop an acidic microenvironment [29, 30] while 
its by-products, specifically dextran, acetone, and methanol, are released in safe 
quantities [31, 32]. Both two-dimensional (2D) and three-dimensional (3D) cell culture 
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experiments were conducted in this study using A549 adenocarcinoma lung cancer cells 
to evaluate Ac-Dex nanoparticles loaded with RSV. Monolayer 2D cell culture has been 
traditionally applied to test the efficacy of therapeutics in vitro because of the ease in 
the evaluation of drug-cell interaction, however 2D models do not accurately represent 
the complex, structural properties of 3D tumors [33, 34]. 3D cell culture provides a 
better in vitro model for tumors with respect to morphology, response to therapeutics, 
growth kinetics, presence of a necrotic core, and diffusion limitations [35-37]. These 
characteristics make the inner core of tumors less accessible for drugs, an effect that is 
not well demonstrated in 2D models. As a result, drugs are only able to affect the outer 
periphery of cells, which may quickly replenish if the core is not also eliminated [38, 
39]. The use of 3D multicellular spheroids is advantageous in testing therapeutic 
efficacy of RSV NP because of their more accurate representation of in vivo solid 
tumors. The aim of this project was to evaluate and compare the chemopreventive effect 
of free RSV and RSV NP on the formation and growth of lung tumor spheroids. We 
hypothesized that RSV NP will inhibit or significantly reduce the growth of tumor cells 
more effectively than free RSV. 
 
3.2.  Methods 
3.2.1.  Synthesis of Acetalated Dextran  
The synthesis of acetalated dextran (Ac-Dex, Figure S1) was conducted as 
previously described [40]. Lyophilized dextran and PPTS were dissolved in anhydrous 
DMSO under N2. The reaction was initiated by the addition of 2-MOP, and lasted for 5 
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minutes, followed by quenching with TEA. The product was then precipitated in basic 
water, frozen overnight, and lyophilized. 
 
3.2.2.  Nuclear Magnetic Resonance Analysis of Acetalated Dextran 
The total acetal coverage (conversion of hydroxyl groups) and type of acetals 
formed was determined by 1H-NMR spectroscopy (Bruker 300 MHz NMR, MA, USA). 
The hydrolysis of acyclic acetals produces methanol and acetone whereas cyclic acetals 
produce only acetone. The total acetal coverage and the cyclic acetal coverage (CAC) 
were determined after normalization of the methanol and acetone peaks in relation to 
dextran (carbon rings). The normalization is associated with the number of protons 
detected on each molecule. The results were expressed per 100 molecules of glucose. 
 
3.2.3.  Preparation of Resveratrol-Loaded Ac-Dex Nanoparticles  
Resveratrol-loaded nanoparticles (RSV NP) were prepared via single emulsion 
and solvent evaporation as described in Supplementary Materials. The organic phase 
was comprised of RSV dissolved in DMSO added to DCM with Ac-Dex and the 
aqueous phase contained 3% PVA in PBS to result in an initial loading of 2 wt% RSV. 
The preparation of fluorescent NP, using curcumin (CUR) as a fluorescent additive, 
followed the same protocol mentioned above, instead adding CUR and no resveratrol to 
the organic phase. Blank NP were prepared similarly, excluding RSV or CUR. 
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3.2.4.  Particle Morphology and Shape Analysis via Scanning Electron 
Microscopy  
The surface morphology and shape of the nanoparticles were evaluated by 
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning 
Electron Microscope (Germany) as described in Supplementary Materials.  
 
3.2.5.  Particle Size, Size Distribution, and Zeta Potential Analysis of 
Nanoparticles 
The size, size distribution (polydispersity index, PDI), and zeta potential of NP 
were measured by dynamic light scattering (DLS) using a Malvern Nano Zetasizer 
(Malvern Instruments, Worcestsershire, UK) as described in Supplementary Materials.  
 
3.2.6.  Analysis of Nanoparticle Drug Loading 
Drug loading (DL) and encapsulation efficacy (EE) of RSV NP were determined 
via ultra performance liquid chromatography (UPLC, LaChrom, Hitachi, Japan), as 
described in Supplementary Materials. The drug loading and encapsulation efficacy 




total	mass	of	nanoparticles × 100 
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EE	(wt%) =
actual	drug	loading	




mass	of	RSV + 	mass	of	Ac − Dex × 100 
 
3.3.  In Vitro Cell Studies 
A549 human epithelial adenocarcinoma cells were cultured in DMEM 
containing FBS, sodium pyruvate, penicillin-streptomycin, and Fungizone at 37 °C and 
5% CO2 as described in Supplementary Materials. 
 
3.3.1.  Two-Dimensional Cell Culture and Cell Viability 
The two-dimensional (2D) in vitro cytotoxic effect of RSV was evaluated in 
A549 cells using an acid phosphatase (AP) colorimetric assay. Cells were seeded into 
flat-bottomed 96-well plates, and were exposed to free RSV in DMSO for 48 and 72 
hours. Details of the assay can be found in Supplementary Materials. pNPP is 
hydrolyzed by the presence of AP in live cells and produces an intense yellow color (p-
nitrophenolate), which was detected at a wavelength of 405 nm in a Biotek Cytation 3 
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The relative viability 
was calculated as the ratio of the fluorescence intensity of the sample (cells dosed with 
RSV) versus the fluorescence intensity of control (cells only). A 2D viability test using 
blank NP was performed to evaluate the effect of different concentrations of NP on 
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A549 cells. The viability of the cells was evaluated at 24, 48, and 72 hours using 
resazurin, and the fluorescence intensity of the samples were detected at 544/590 nm. 
 
3.3.2.   RSV Nanoparticle Cellular Uptake 
Confocal fluorescence microscopy images were taken of A549 cells exposed to 
100 µM CUR NP for 3 hours as described in Supplementary Materials. The cells were 
stained with CellMaskTM deep red plasma membrane and fixed with 4% 
paraformaldehyde in PBS. For quantification, A549 cells were seeded in a flat-bottomed 
96-well plate and exposed to 100 µM CUR NP for 3 hours. After exposure, the particle 
solution was removed, and cells were washed with glycine and cold PBS prior to 
fixation in with ethanol. Uptake was quantified using fluorescence spectroscopy at 
420/540 nm.  
 
3.3.3.  Formation and Evaluation of 3D Multicellular Spheroids 
A549 multicellular spheroids (MCS), representing a three-dimensional (3D) cell 
culture platform, were formed via centrifugation to evaluate the in vitro effects of RSV 
formulations (details found in Supplementary Materials). Initially, three cell 
concentrations (3,000, 5,000, and 8,000 cells/well) with 20 µg/mL of collagen type I 
were seeded into ultralow attachment round-bottomed 96-well plates, centrifuged, and 
incubated for growth observation. Bright-field images were taken at various time points 
up to day 22 using a Biotek Cytation 3 imager. The MCS average size and morphology 
of the spheroids was evaluated over time. Viability of sample MCS was determined 
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using live/dead assay at days 1 and 5 of MCS growth. The live/dead solution contained 
ethidium homodimer-1 (red dye to detect dead cells), and calcein AM (green dye for 
live cells). The MCS were incubated with live/dead solution for 60 min before imaging. 
 
3.3.4.  Growth Inhibition of Multicellular Spheroids Exposed to Free RSV and 
RSV NP 
The growth inhibition of A549 MCS was evaluated in two types of studies 
(prevention or treatment) with free RSV and RSV NP. For prevention studies, MCS 
were dosed with free RSV or RSV NP on the day cells were seeded, following 
centrifugation of the plates. For treatment studies, MCS were dosed with free RSV and 
RSV NP 5 days after MCS seeding and formation. In both prevention and treatment 
studies, the plates were incubated at standard conditions and were imaged periodically 
(bright-field) and analyzed for size using a Biotek Cytation 3 imager. The growth or 
inhibition of MCS was analyzed by calculating the change in size relative to untreated 
controls.  
 
3.3.5.  Clonogenic Assay 
A clonogenic assay was performed on MCS dosed with free RSV after 
prevention and treatment studies to test the ability of cells to recover and form colonies 
as outlined in Supplementary Materials.  
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3.4.  Statistical Analysis 
 Measurements were performed in at least triplicate. All values were 
presented as mean ± standard deviation.  The half maximal inhibitory concentration 
(IC50) values were calculated using a polynomial regression in PRISM version 5.0 
software (GraphPad Software, Inc., CA, USA). The statistical significance of the results 
was determined using Student’s t-test. Statistical significance was defined as p < 0.05 
(*). 
 
3.5.  Results 
 
3.5.1.  Characterization of Acetalated Dextran  
The reaction between dextran and 2-MOP in the presence of PPTS resulted in 
the synthesis of acetalated dextran (Ac-Dex), which contains both cyclic and acyclic 
acetal groups (Figure S1). NMR spectrometry of Ac-Dex showed a total acetal coverage 
(conversion from –OH groups) of 80% and a cyclic acetal coverage of 75%.   
 
3.5.2.  Characterization of Nanoparticles 
3.5.2.1.  Nanoparticle Size, Distribution, and Surface Charge  
NP size, polydispersity index (PDI), and zeta potential values determined by 
DLS are shown in Table 3.1. RSV NP and Blank NP exhibited diameters near 200 nm, 
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with high homogeneity as demonstrated by their narrow size distribution (PDI of 0.12), 
and surface charges of -2.6 and -5.6 mV for RSV NP and Blank NP, respectively. SEM 
imaging (Figure 3.1) revealed smooth surface morphology, spherical shape, and 
confirmed the narrow size distribution and homogeneity shown by DLS measurements.  
 
Table 3.1  Characteristics of resveratrol (RSV)-loaded nanoparticles (RSV NP), blank 
NP without RSV (Blank NP), and curcumin (CUR)-loaded NP (CUR NP), including 
diameter, polydispersity index (PDI), zeta (ζ) potential, RSV loading, and encapsulation 













RSV NP 205.2 ± 5.6 0.12 ± 0.04 -2.94 ± 0.36 14.63 ± 2.25 73.65 ± 11.62 
Blank NP 192.0 ± 3.4 0.12 ± 0.02 -5.63 ± 1.29 N/A N/A 
CUR NP 175.8 ± 8.1 0.15 ± 0.03 -4.13 ± 0.48 14.73 ± 0.11(*) N/A 
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Figure 3.1  Representative scanning electron micrographs of (Left) blank nanoparticles 
and (Right) resveratrol-loaded nanoparticles. Scale bar = 500 nm. 
 
3.5.2.2.  RSV Loading in Nanoparticles 
Ac-Dex nanoparticles (NP) were successfully loaded with resveratrol (RSV), 
demonstrating an encapsulation efficacy of 73% (Table 3.1). The RSV NP drug loading 
was 14.6 µg RSV/mg NP (max = 20 µg/mg).  
 
3.5.3.  Cell Studies 
 
3.5.3.1.  Two-Dimensional Cell Culture and Cell Viability 
Cell viability studies using A549 cells in a monolayer (2D) culture, when dosed 
with free RSV, resulted in IC50 values of 121.9 µM and 74.6 µM at 48 hours and 72 
hours of exposure, respectively (Figure A.2). The amount of DMSO in cells was set to 
a concentration of 0.15 v/v % to enable dissolution of RSV in media, and no negative 
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effects on the cells from DMSO were observed with respect to viability analysis. Cell 
viability evaluation of free RSV was carried out on 3D MCS; however, there was no 
correlation between RSV concentration and cell viability (Figure A.2C). 2D A549 cells 
exposed to Blank NP demonstrated a significant reduction in relative viability at NP 
concentrations above 3 mg/ml (Figure 3.2A), whereas cells exposed to 0.05 - 1 mg/ml 




Figure 3.2  Viability analysis of blank nanoparticles without resveratrol (Blank NP) and 
uptake of curcumin (CUR)-loaded NP (CUR NP). (A) Relative viability of A549 cells 
exposed to Blank NP (*p < 0.05, **p < 0.01, ***p < 0.001, and n ³ 3, which represent 
comparison to the control with no exposure to NP). (B) Confocal images of CUR NP 
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uptake in A549 cells, showing CUR NP (green) and cell membrane (red), scale bar = 
20 µm. (C) Fluorescence quantification of CUR NP uptake in A549 cells. 
 
3.5.3.2.  Cellular Uptake of RSV NP in A549 Cells 
The cellular uptake of NP into 2D A549 cells was evaluated using CUR NP as 
model fluorescent NP. The CUR NP characteristics (Table 3.1) are similar to both RSV 
NP and Blank NP with respect to size, PDI, surface charge, and drug loading. A 
representative confocal image (Figure 3.2B) shows NP associated within the cytoplasm 
of A549 cells. Quantification of uptake is illustrated in Figure 3.2C, where CUR NP 
were effectively uptaken in A549 cells compared to the control (cells only).   
 
3.5.3.3.  Formation, Size Analysis, and Morphology of Multicellular Spheroids  
Three concentrations of A549 lung adenocarcinoma cells were initially seeded 
to form MCS via centrifugation, and were imaged over time to evaluate their growth. 
As seen in Figure 3.3A, the growth curves of spheroids with 5,000 and 3,000 cells/MCS 
overlapped, while samples with 8,000 cells/MCS started larger but did not reach the 
same maximum size. From these studies, 5,000 cells/MCS were chosen as the optimized 
MCS. A live/dead assay was performed on 1-day and 5-day MCS. Figure 3.3B shows 
the presence of live cells (green) in the outer region of the MCS and dead cells (red) in 
the inner core. From day 1 to day 5, the MCS increased in size, the volume of dead cells 
increased, and the region of live cells at the surface decreased. 
 
   49 
  MCS formation and growth for 5,000 cells/MCS is presented in Figure 3.3C. 
A549 cells were initially aggregated in a 2D monolayer, but formed an organized cluster 
of cells after four hours. A defined spheroid was present within 24 hours and MCS 
continued to grow for over two weeks, after which the MCS size decreased. Maximum 
MCS size (828 µm) was reached on day 17. For the last two days, it was observed that 




Figure 3.3  Optimization of A549 multicellular spheroid (MCS) formation. (A) Growth 
analysis of A549 MCS grown at different initial cell seeding concentrations; (B) 
Fluorescence images showing MCS morphology and viability on days 1 and 5, where 
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green cells represent live cells and red cells represent dead cells (Scale bar = 300 µm); 
and (C) Bright-field images of A549 cells grown at 5,000 cells/MCS for 22 days (Scale 
bar = 500 µm). **p < 0.01 which represents comparison of 8,000 cells/MCS to 5,000 
and 3,000 cells/MCS on day 22. 
 
 
3.5.3.4.  Growth Inhibition of Multicellular Spheroids 
3.5.3.4.1.   Prevention Studies 
For the prevention study, MCS were dosed with free RSV and RSV NP after 
seeding and centrifugation on day 0. Bright-field images were taken, and the diameters 
of the spheroids were recorded over time. MCS exposed to 500 µM of free RSV showed 
complete inhibition of growth and reduction in size, whereas MCS exposed to 250 µM 
showed significant growth inhibition (Figure 3.4A). MCS exposed to 25, 50, and 100 
µM RSV showed delayed growth. Exposure to media with 0.15 v/v % DMSO had no 
impact on MCS growth. The outcome following RSV NP dosing can be seen in Figure 
3.4B. 250 and 500 µM RSV NP completely inhibited the formation of MCS (no visible 
MCS). MCS exposed to 25 µM of RSV NP did not show a significant difference 
compared to control, 50 µM RSV NP resulted in significant growth inhibition, and 100 
µM RSV NP resulted in a reduction in size of MCS. 
The change in spheroid diameters relative to the control on day 15 is shown in 
Figure 3.5C. Neither Blank NP nor 0.15 v/v % DMSO (Control-D) had an impact on 
MCS growth. At 50 and 100 µM RSV, spheroid growth inhibition significantly 
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increased using RSV-loaded nanoparticles compared to free RSV. MCS exposed to 250 
and 500 µM free RSV resulted in MCS growth inhibition or reduction, whereas 
exposure to 250 and 500 µM RSV NP resulted in no MCS formation. Bright-field 
images of MCS dosed with 100 µM RSV formulations and comparative graph bars with 
control are shown in Figures 3.6A. Free RSV and RSV NP resulted in spheroid size 
reduction, with RSV NP being more effective than free RSV at reducing MCS size on 




Figure 3.4  Evaluation of multicellular spheroid (MCS) growth prevention using 
different resveratrol (RSV) formulations, including (A) free RSV (RSV) and (B) RSV-
 
   52 
loaded nanoparticles (RSV NP). Control-D refers to media with 0.15 v/v % DMSO. (C) 
Comparison of the change in MCS diameter relative to control (no RSV exposure) 
between free RSV and RSV NP at day 15. *p < 0.05, **p < 0.01, ***p < 0.001, which 
represents comparison to the control (no exposure to RSV or RSV NP) for (A) and (B) 





3.5.3.4.2.  Treatment Studies 
For the treatment studies, MCS were dosed with free RSV and RSV NP 5 days 
after MCS growth began. No differences were observed between the control MCS and 
MCS exposed to lower free RSV concentrations (< 100 µM RSV), however MCS 
exposed to 250 µM free RSV experienced a reduction in size and those exposed to 500 
µM experienced a delay in growth (Figure 3.5A). All MCS exposed to RSV NP 
experienced significant inhibition of spheroid growth (Figure 3.5B). From days 1 to 5, 
MCS grew similarly, and after being dosed with RSV NP they experienced a distinct 
reduction in growth, which was not observed for MCS exposed to free RSV. A 
significant inhibition in MCS growth was observed using RSV NP versus free RSV at 
day 15 at concentrations ranging from 25 to 250 µM RSV (Figure 3.5C). Growth was 
completely inhibited in MCS exposed to 500 µM RSV (free or NP). In addition, MCS 
exposed to Blank NP corresponding to 100 µM and 500 µM RSV were evaluated, where 
the higher concentration inhibited the growth of MCS, while 100 µM did not affect 
MCS growth. Bright-field images of MCS dosed with 100 µM RSV formulations and 
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comparative graph bars with control are shown in Figures 3.6B. MCS size was reduced 




Figure 3.5  Evaluation of multicellular spheroid (MCS) treatment (growth restriction) 
using different resveratrol (RSV) formulations, including (A) free RSV (RSV) and (B) 
RSV-loaded nanoparticles (RSV NP). Control-D refers to media with 0.15 v/v % 
DMSO. (C) Comparison of the change in diameter relative to control between free RSV 
and RSV NP at day 15. *p < 0.05, **p < 0.01, ***p < 0.001, which represents 
comparison to the control (no exposure to RSV or RSV NP) for (A) and (B) and 
represents comparison between RSV and RSV NP for (C); n ³ 3. 
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Figure 3.6  Comparison of A549 multicellular spheroid (MCS) growth in (A) 
prevention and (B) treatment studies upon exposure to 100 µM resveratrol (RSV) 
formulations. Bright-field images and corresponding quantification of MCS growth 
upon exposure to free resveratrol (RSV), RSV-loaded nanoparticles (RSV NP), and 
Blank NP equivalent to 100 µM RSV NP by mass. Control MCS were exposed to media 
only. Scale bar = 500 µm. *p < 0.05, **p < 0.01, ***p < 0.001, which represents 
comparison to the control (no exposure to RSV or RSV NP) for each time point; n ³ 3. 
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3.5.3.5.  Clonogenic assay 
Cells from MCS dosed with free RSV in prevention and treatment studies were 
seeded to determine their recovery and potential to form colonies (Figure 3.7). For 
prevention, the formation of colonies followed a similar pattern seen in the inhibition of 
growth of MCS, where an increase in RSV concentration resulted in an increase in the 
inhibition of colony formation (Figure 3.7A). In contrast, for treatment, cells from the 
MCS treated with free RSV formed similar numbers of colonies, irrespective of RSV 






Figure 3.7  Clonogenic assay results for A549 cells recovered from multicellular 
spheroids dosed with free resveratrol (RSV) in (A) prevention studies and (B) treatment 
studies. Control DMSO refers to media with 0.15 v/v % DMSO.  Data is presented as 
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the number of colonies compared with the untreated control (mean ± standard deviation, 
n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, which represents comparison to the control 
(no exposure to RSV); n ³ 3. 
 
3.6.  Discussion 
The quality of Ac-Dex is important in order to obtain favorable nanoparticle 
formulation and characteristics. During Ac-Dex synthesis, dextran transitions from 
hydrophilic to hydrophobic due to the conversion of -OH groups to acetals. High acetal 
coverage enables the stability of PVA-coated NP (small size and distribution), 
according to previous studies [41]. High -OH conversion and CAC coverage allow Ac-
Dex to exhibit pH-tunable hydrolysis-driven degradation, which allows it to degrade in 
acidic conditions more readily than neutral conditions [42]. 
The small NP sizes and high homogeneity is confirmed via SEM, which showed 
homogeneous, spherical NP. NP observed in SEM images were smaller than water-
dispersed NP measured by DLS, due to shrinkage of the particles following drying [43]. 
DLS measures the hydrodynamic diameter of particles in aqueous suspension, allowing 
for a hydrated layer on the surface of NP. While neutral and slightly polar molecules 
have the tendency to agglomerate in aqueous environments, and Ac-Dex NP exhibited 
a slightly negative charge, the particles were well dispersed in water due to their PVA 
coating. PVA coating is known to improve colloidal stability and reduce the 
agglomeration of nanoparticles due to its steric effect [44, 45].  
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2D cell culture models have been extensively used in the evaluation of 
therapeutics for preliminary drug screening. In this project we determined the in vitro 
therapeutic concentrations of RSV using a monolayer of cells prior to translation into a 
more complex system.  Following 2D viability analysis cells exposed to pure RSV 
experienced a 40% reduction in the IC50 value after 72 hours instead of 48 hours, 
demonstrating that a longer exposure time reduces the RSV demand during treatment. 
2D cells exhibited increased cell viability when exposed to low concentrations of Blank 
NP (< 1 mg/ml), which likely indicates that dextran released following the degradation 
of Ac-Dex may have been used as a nutrient by the cells. In contrast, exposure to higher 
Blank NP concentrations (> 3 mg/ml) resulted in significant viability reduction, which 
was also observed in the 3D spheroid model. 
In preliminary 2D uptake studies, RSV and CUR were co-encapsulated in NP, 
however, a decrease in cell number was noticed after one hour of exposure because of 
the therapeutic effect of RSV (data not shown). As a result, CUR was used as a 
fluorescent model compound for the uptake studies. CUR is a small molecular weight 
compound, and CUR NP exhibited similar size and surface charge to RSV NP. Previous 
studies have shown that 100-200 nm nanoparticles can be internalized in cells [46]. RSV 
NP and CUR NP are within this optimal size range, and CUR NP were successfully 
internalized by A549 cells after three hours. The accumulation of NP within the cells 
can allow for RSV to be released into the cells and exert its chemotherapeutic effect. 
Evaluation of NP using 3D multicellular spheroids (MCS) offer advantages over 
2D culture because MCS offer a better representation of the structure of in vivo tumors 
and the resulting drug-cell interactions. The maximum MCS size for the three cell 
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seeding concentrations was reached at day 17, followed by a period where MCS sizes 
decreased. This behavior was likely caused by an exhaust in nutrients from media, as it 
was not replenished throughout the experiment. 3,000 and 5,000 cells/MCS samples 
exhibited overlapping growth curves starting at day 7, which may be due to nutrient 
limitations in the larger population of cells.  
MCS larger than 200 µm in diameter are known to display a heterogeneous 
structure with a peripheral proliferating region, an intermediate quiescent region due to 
limited oxygen and nutrients transport, and an inner necrotic core [47-49]. Larger 
spheroids (> 500 µm) present a similar physicochemical gradient to that seen in 
micrometastasis and 0.5 - 1 mm3 avascular tumors [50, 51]. In this study, 3D MCS 
generated via centrifugation developed morphology similar to tumors with respect to a 
proliferating outer surface and core with dead cells. These findings are consistent with 
other studies that demonstrate similar features at  > 4 days [51]. The lack of correlation 
observed during the viability evaluation of RSV in 3D MCS using acid phosphatase 
assay is likely attributable to the physical barriers of MCS structure and inability of RSV 
and assay reagents to fully penetrate the spheroids [52, 53]. Given the extensive cell-
cell interactions in MCS, they provide a much more formidable barrier than the 2D 
monolayer [54, 55].  
In order to determine the therapeutic potential of RSV NP in the inhibition of 
MCS growth, preventive and treatment studies were completed comparing free RSV 
and RSV NP. In preventive studies, inhibition in the growth of MCS was observed for 
50 µM and 100 µM of free RSV, and this effect was significantly enhanced upon 
exposure to RSV NP. These findings imply an enhanced preventive effect of RSV in a 
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nanoparticle formulation. In treatment studies, MCS were dosed at day 5, after MCS 
had developed morphology similar to an in vivo tumor, as opposed to a cluster of 
individual cells. Following RSV treatment, spheroid growth decreased for all RSV NP 
concentrations. This outcome demonstrates another potential application of RSV in a 
nanoparticle formulation for treatment of solid tumors. 
In both preventive and treatment studies, exposure to 500 µM RSV resulted in a 
significant reduction in MCS growth, which was enhanced by the NP carrier. As a 
comparison, the effect of Blank NP was evaluated, where cytotoxicity at this 
concentration was enhanced by the presence of NP alone. High NP concentrations likely 
interfered with the aggregation of cells during MCS formation.  
50 and 100 µM RSV NP enhanced the properties of free RSV and may serve as 
a potential chemopreventive formulation for lung cancer. In previous studies, higher 
concentrations of free RSV (>100 µM) resulted in mitochondrial dysfunction and 
promoted apoptosis in human hepatoblastoma cells [56] and also with RSV solid lipid 
NP that were used as an effective neuroprotectant in glioma cells [57]. The polymer 
effect on formulation safety was previously evaluated in a PLGA system, where a 
concentration of 50 µM of RSV-loaded PLGA NP was found to be beneficial as an 
antioxidant in cochlear cells and remained under the cytotoxic limits of NP [58]. The 
RSV-loaded Ac-Dex NP system developed on this project agreed with these findings. 
Individual cells from MCS exposed to RSV in preventive and treatment studies 
exhibited different behaviors in colony formation colonies. While cells from preventive 
studies had a weaker recovery and inferior ability to form colonies compared to control; 
they showed no difference in colony formation compared to control in treatment studies, 
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demonstrating the ability of cells from MCS to recover after dosing on fully-formed 
spheroids (treatment studies). These findings suggest that prevention chemotherapy 
might be advantageous for reduced cancer recurrence. 
 
3.7.  Conclusions  
We developed a resveratrol-loaded nanoparticle formulation based on Ac-Dex, 
a biodegradable polymer synthesized from dextran, resulting in spherical RSV NP that 
exhibited homogeneous dispersion, smooth surface, and appropriate size for cellular 
uptake. The evaluation of RSV NP in the inhibition of A549 tumor spheroid growth 
showed that this chemopreventive agent has an enhanced therapeutic effect as a 
nanoparticle formulation when compared to free RSV. High concentrations of RSV NP 
were seen to inhibit the formation of MCS, while lower concentrations RSV NP 
significantly reduced the growth of tumor spheroids. The results were consistent in both 
types of studies, with prevention of tumor cell aggregation and in the treatment of 
already developed solid tumor spheroids. These findings represent potential alternative 
uses for RSV NP, in chemoprevention and treatment of lung cancer tumors.  
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Paclitaxel is the most applied chemotherapeutic for the treatment of lung cancer, 
delivered as Taxol Intravenously. The purpose of this project was to develop a dry 
powder nanocomposite microparticle (nCmP) aerosol containing PTX-loaded 
nanoparticles (NP) to be delivered via a dry powder inhaler to the lungs for the treatment 
of non-small cell lung cancer (NSCLC) and subsequently to compare its efficacy vs. 
free PTX. Nanoparticles were formulated by a single emulsion and solvent evaporation 
method, producing smooth, almost neutral PTX NP of around 200 nm in size. PTX 
nCmP were obtained via a spray drying formulation, producing amorphous wrinkled 
particles that demonstrated optimal deposition in vitro pulmonary delivery.  Particles 
were evaluated in a 2D followed by 3D cell culture studies. PTX NP enhanced 
cytotoxicity when compared to pure drug in the 2D model.  However, in the LCC 3D 
model, PTX NP and pure PTX showed similar efficacy in growth inhibition of 
multicellular spheroids, likely due to diffusion and penetration limitations. Overall, the 
formulation had comparable cytotoxicity responses in multicellular spheroids compared 
with free PTX. Finally, PTX nCmP were evaluated in an AIC 3D platform that mimics 
the pulmonary environment, representing a new model for the assessment of dry powder 
formulations.   
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PTX, paclitaxel; NP, nanoparticles; Ac-Dex, acetalated dextran; CUR, 
curcumin; CAC, cyclic acetal coverage; 2D, two-dimensional; 3D, three-dimensional; 
MCS, multicellular tumor spheroids; PPTS, pyridinium p-toluenesulfonate; DMSO, 
dimethyl sulfoxide; 2-MOP, 2-methoxypropene; TEA, triethylamine; DCM, 
dichloromethane; PVA, polyvinyl alcohol; PBS, phosphate buffered saline (1X PBS 
dilution unless specified); NMR, nuclear magnetic resonance; DLS, dynamic light 
scattering; PDI, polydispersity index; DL, drug loading; EE, encapsulation efficacy; 
UPLC, ultra-performance liquid chromatography; DMEM, Dulbecco’s modified 
Eagle’s medium; RPMI, Roswell Park Memorial Institute; FBS, fetal bovine serum; 
DSC, differential scanning calorimetry; PXRD, powder X-ray diffraction; KF, Karl 
Fischer titration; NGI, Next Generation Impactor; FPD, fine particle dose; FPF, fine 
particle fraction; RF, respirable fraction; ED, emitted dose; DPI, dry powder inhaler; 
LCC, liquid covered culture; AIC, air interface culture 
4.1.  Introduction 
Lung & bronchus cancer is the leading cause in cancer related deaths in the USA, 
with an estimated of 228,150 new cases in 2019 and a mortality of 390 deaths per day. 
The 5-year relative survival rate of a patient diagnosed with lung cancer is only 19% 
[1]. Chemotherapy, among the traditional treatment options, has been extensively 
applied for lung cancer with the use of potent drugs intravenous (I.V.) delivered. 
Systemic delivery is associated with high toxicity through the body, high dosage 
demand, and low specificity in the delivery system. Pulmonary delivery has emerged as 





overcome some limitations seen in traditional I.V. delivery [2]. Aerosols often involve 
a non-invasive delivery system that uses lower doses of drug with fewer systemic side 
effects [3, 4]. 
Dry powder inhalers (DPIs) are preferred over other aerosols devices because it 
promises physical stability of the formulation in solid form, is portable and easy to use, 
and can be applied to a wide variety of active ingredients and dose weights [5, 6]. While 
big particles are easily removed from the airways, due to the lung phagocytosis is 
maximized at particles of 1-2µm in diameter [7], nanocarriers have the advantage of 
deeper deposition in the lungs, improved colloidal stability of hydrophobic drugs, and 
sustained release of the therapeutic, which will consequently reduce the dose frequency 
[8]. 
Particle deposition in the lungs is dependent on its size, morphology, density, 
among others [9]. However, the aerosol performance of the particles will be governed 
by its aerodynamic diameter [10]. Larger particles are deposited in the airways by 
impaction and sedimentation, while smaller particles deposit by diffusion (Brownian 
motion) [11, 12]. The optimal particle size for deep lung deposition has been established 
to have an aerodynamic diameter between 1 and 3 µm [12]. In this regard, the NP 
deposition is limited because of the low inertia and high possibility to be exhaled. 
Aggregates of nanoparticles at a micro-size scale (i.e. nanocomposite microparticles) 
are thought to have enough mass to deposit effectively into the lungs and respond to 
impaction and sedimentation mechanisms. Once the micro-sized particles deposit in the 
airways, they dissociate back into nanoparticles [13, 14]. Nanocomposite microparticles 





and tunable lung deposition while delivering NP with cargo upon arrival to the different 
regions in the lungs [15](Wang, 2017 Optimization). 
Paclitaxel (PTX) is a microtubular stabilizer commonly used in cancer 
treatment, characterized by its high toxicity, low water solubility (~0.4 µg/ml) and need 
to use excipients for its IV delivery [16]. The hydrophobicity nature of PTX limits its 
bioavailability and application, thus many companies are developing nanocarriers 
loaded with PTX, using polymeric micelles, liposomes, nanoemulsions [17].  
The initial evaluations of therapeutics are assessed in a 2-dimentional (2D) 
monolayer of cells. However, in many cases this platform does not accurately represent 
the complex tumor morphology nor translate into similar results in vivo [18]. This 
misrepresentation may be due to the lack of dense extracellular matrix produced [19], 
or cell-particle interactions observed in real tumors [20, 21]. 
Cancer cells tend to form solid tumors that are characterized for having hypoxic 
cells and a necrotic core, which gives them high resistance to treatment. One reason for 
the failure of cancer treatments is the low concentration of drug in tumors due to 
transport and diffusion limitations [22]. Various techniques have been expanded to 
fabricate in vitro multicellular spheroids (MCS) [23-26], that at sizes over 200 µm, 
develop an outer proliferating region, an intermediate quiescent region and a hypoxic 
necrotic core, representing better solid tumors in vivo. [27-29]. The 3D MCS are able to 
accurately mimic features such as spatial architecture, cell-cell signaling, physiological 
responses, gene expression patters, and drug resistance mechanisms, which represent a 





On this project we developed, characterized, and evaluated PTX nanocomposite 
microparticles for the treatment of lung cancer. We hypothesized that nCmP will 
effectively deposit in the lungs and disaggregate to liberate NP that will be uptaken by 
the cells. We encapsulated PTX in Acetalated dextran (Ac-Dex), a biodegradable 
polymer, tunable polymer derived from dextran [32], via a single emulsion and solvent 
evaporation technique. PTX nanoparticles (PTX NP) were then spray dried with 
mannitol to form the nanocomposite microparticles that were characterized for lung 
deposition using the next generation impactor (NGI). The efficacy of the formulations 
was evaluated in a 2D cell culture study followed for 3D LLC for NP and 3D AIC 
platform for the evaluation of PTX nCmP. The dry powder formulation showed 
excellent aerodynamic performance and stability for broad and deep lung deposition, 
with a good re-dispersion and a comparable cytotoxicity to pure PTX, being a strong 
candidate for the current treatment of lung cancer. The 3D AIC platform developed may 
help in the early evaluation of dry powder formulations in a more accurate and 
representative manner.  
 
4.2.  Materials and Methods 
4.2.1.  Materials 
Dextran from Leuconostic mesenteroides (MW 9,000-11,000), pyridinium p-
toluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), 2-
methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥ 99%), deuterium chloride 





anhydrous sodium acetate, D-mannitol (≥ 98%), TritonTM X-100, bisBenzimide H 
33342 trihydrochloride (Hoechst 33342), methanol (HPLC grade, ≥ 99.9%), and acetic 
acid (≥ 99%) were obtained from Sigma-Aldrich (Natick, MA, USA). Deuterium oxide 
(D2O, 99.8% atom D), polyvinyl alcohol (PVA, 88% hydrolyzed, average MW 22,000), 
and curcumin (CUR, > 98%) were obtained from Acros Organics (Geel, Belgium). 
Formic acid (FA, ≥ 99.5%), glycine (≥ 98.5%), and HydranalTM Coulomat AG 
Honeywell were obtained from Fisher Scientific (Somerville, NJ, USA). Phosphate 
buffered saline 10X (PBS) was obtained from Research Products International (RPI) 
(Mount Prospect, IL, USA). Paclitaxel (> 99.5%) was purchased from LC Laboratories 
(Woburn, MA, USA). A549 human lung adenocarcinoma epithelial cells and NCl-H441 
(H441) lung papillary adenocarcinoma epithelial cells were obtained from American 
Type Culture Collection (ATCC, Manassas, VA, USA). Fetal bovine serum (FBS) was 
obtained from Atlanta Biologics (Flowery Branch, GA, USA). RPMI 1640 1X with L-
glutamine and 25 mM HEPES and collagen rat tail type I were obtained from Corning 
Inc. (Corning, NY, USA). Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L d-
glucose and L-glutamine), trypsin-EDTA (0.25%) phenol red, calcein AM, and 
ethidium homodimer-1 were obtained from Life TechnologiesTM (Carlsbad, CA, USA). 
Sodium pyruvate, penicillin streptomycin, and Fungizone were obtained from GE 
Health Life Sciences (Pittsburgh, PA, USA).  
 
4.2.2.  Synthesis of acetalated dextran (Ac-Dex)  
The synthesis of acetalated dextran (Ac-Dex) was conducted as previously 





dissolved in anhydrous DMSO under pure N2 atmosphere. Dextran was reacted with 2-
MOP for 5 minutes and the reaction was quenched with TEA. The product was then 
precipitated in basic water, vacuum filtered, frozen overnight, and lyophilized (-50°C, 
0.03 mBar) for 48 hours to remove residual water. 
 
4.2.3.  Nuclear magnetic resonance (NMR) analysis of acetalated dextran (Ac-
Dex)  
The conversion of hydroxyl groups (total acetal coverage) and the cyclic acetal 
coverage (CAC) were determined by using 1H-NMR spectroscopy (Bruker 300 MHz 
NMR, MA, USA). In an NMR tube, 10 mg of Ac-Dex was suspended in 700 µL of D2O, 
and then hydrolyzed with 30 µL of DCl. The hydrolysis of acyclic acetals produces 
methanol and acetone whereas cyclic acetals produce only acetone. The total acetal 
coverage and the CAC were determined after normalization of the methanol and acetone 
peaks in relation to dextran (carbon rings). The normalization is associated with the 
number of protons detected on each molecule, and the results were expressed per 100 
molecules of glucose. 
 
4.2.4.  Preparation of PTX-loaded Ac-Dex nanoparticles (PTX NP) 
Paclitaxel-loaded nanoparticles (PTX NP) were prepared via a single emulsion 
and solvent evaporation method. 50 mg of PTX was dissolved in 1 mL of DMSO and 
200 µL of this solution was added to 1800 µL of DCM. 1 mL of the PTX DCM solution 





6 mL of 3% PVA in PBS (aqueous phase) was added to the organic phase and sonicated 
(Q500 Sonicator, Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off 
pulse at an amplitude of 70% (100% amplitude = 120 µm). The resulting emulsion was 
transferred to a 40 mL spinning solution of 0.3% PVA in PBS and stirred for 4 hours to 
evaporate the organic solvent and stabilize the nanoparticles. The final solution was 
centrifuged at 12,000 rpm (19,802 g) and 4 °C for 20 minutes. The nanoparticles were 
washed twice with basic water, frozen, and lyophilized (-50°C, 0.03 mBar) for 24 hours.  
For the preparation of fluorescent NP for imaging (CUR NP), 1 mg of curcumin 
(CUR, fluorescent reagent) was dissolved in 1 ml DCM and added to 39 mg of Ac-Dex 
(organic phase) and made similar to the steps described above. Blank NP were made 
following the same procedures as CUR NP and PTX NP, excluding any dye or 
therapeutic. 
 
4.2.5.  Formulation of PTX nanocomposite microparticles (PTX nCmP) via spray 
drying 
Paclitaxel nCmP were formulated with PTX NP and mannitol in an aqueous 
suspension using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, Switzerland) in 
open mode. The ratio of PTX NP: mannitol was 80:20 (w/w) in DI water, which was 
suspended at a feed concentration of 0.5% (w/v). The spray dryer conditions were: 414 
L/h dry N2 flow rate, aspiration rate of 28 m3/h, pump rate of 0.9 mL/min, inlet 
temperature of 90 °C, and nozzle cleaner rate of 4. The nCmP were collected in an 





4.2.6.  Particle morphology and shape analysis via scanning electron microscopy 
(SEM) 
The surface morphology and shape of the nanoparticles (NP) and nCmP were 
evaluated by scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field 
Emission-SEM (Germany). NP were suspended in basic water at a concentration of 10 
mg/ml, dropped onto aluminum SEM stubs, and dried at room temperature. nCmP 
samples were placed on SEM stubs covered by double-sided adhesive carbon tabs. Both 
types of samples were sputter coated with a thin film of gold/palladium alloy a BIO-
RAD system at 20 µA for 60 seconds under argon gas. Images were captured at 5 kV 
and at various magnifications. 
 
4.2.7.  Particle size, size distribution, and zeta potential analysis of NP and nCmP 
The hydrodynamic size, size distribution (expressed by polydispersity index, 
PDI), and zeta potential of NP and re-dispersion NP from nCmP were measured by 
dynamic light scattering (DLS) using a Malvern Nano Zetasizer (Malvern Instruments, 
Worcestsershire, UK). NP were suspended in basic water (0.5 mg/mL, pH 9), vortexed, 
and sonicated for one minute and measurements were performed at 25°C. The 
theoretical sizes of dry NP and nCmP were analyzed by measuring the diameter of at 






4.2.8.  Analysis of PTX loading in PTX NP and PTX nCmP 
Drug loading (DL) of PTX NP and nCmP was determined via ultra-performance 
liquid chromatography (UPLC, LaChrom, Hitachi, Japan). The detection of PTX was 
performed using an Ascentis column (C18, 5 µm x 150 mm x 4.6 mm). The UPLC 
conditions were as follows: pump rate of 1 ml/min, absorbance of 227 nm, temperature 
of 25°C, 20 µL per injection, 4-minute retention time, and a mobile phase containing 
60% acetonitrile and 40% DI water. PTX NP and PTX nCmP samples were completely 
dissolved in mobile phase (1 mg/mL) prior to analysis. The PTX concentration was 
quantified by comparison with a standard calibration curve of PTX in the mobile phase. 




























4.2.9.  In vitro PTX release from NP and nCmP 
The in vitro release profiles of PTX from NP and nCmP were determined via a 
release study of suspended particles (1 mg/mL, 1.7 mL) in modified phosphate buffer 
(PBS, 0.1 M, pH 7.4, 0.5% wt% Tween 80) and modified acetate buffer (0.1 M, pH 5, 
0.5% wt% Tween 80). The suspensions were incubated at 37°C and 100 rpm (Digital 
Heat Block and Orbi shaker, Benchmark Scientific, Edison, NJ, USA). At various time 
points (0-7 days), particle samples were centrifuged at 23,102 g for 5 minutes at 4°C to 
isolate the NP. 200 mL of supernatant was withdrawn and replaced by the same amount 
of fresh buffer. The supernatant samples were analyzed for PTX content by UPLC 
following the same method described previously. 
 
4.2.10.  Differential scanning calorimetry (DSC) 
The thermal phase transitions of NP, nCmP, and raw materials were determined 
by DSC using a TA Q10 DSC system (TA instruments, New Castle, DE, USA) equipped 
with an automated computer-controlled cooling system. 1-3 mg of sample was weighed 
into TzeroTM alodine-coated aluminum pans, which were hermetically sealed. The 
sealed sample pan was placed in the DSC chamber along with an empty sealed reference 
pan, which were heated from 0-300 °C at a rate of 10 °C/min. 
 
4.2.11.  Powder X-ray diffraction (PXRD) 
PXRD was applied to determine the crystalline nature of nCmP and its raw 





with Cu Ka radiation source (40KV, 44mA). The samples were placed in a horizontal 
slit holder prior to analysis. The scan range was 5-60° in 2q at a sampling width of 0.1 
and scan speed of 1°/min. 
 
4.2.12.  Karl Fischer coulometric titration  
The water content of nCmP was quantified by Karl Fischer (KF) coulometric 
titration using a 737 KF coulometer (Metrohm, Riverview, FL, USA). 10 mg of particles 
were dissolved in a known mass of anhydrous methanol and injected into the reaction 
cell filled with Hydranal® KF reagent. The water content was analyzed and reported in 
wt%. Pure solvent was analyzed as background sample.  
 
4.2.13.  In vitro aerosol dispersion performance with a Next Generation Impactor 
(NGI) 
The in vitro aerosol dispersion of dry powder nCmP was evaluated using a Next 
Generation ImpactorTM (NGITM, MSN Corporation, Shoreview, MN, USA) equipped 
with a stainless-steel induction port attachment (USP throat) and gravimetric NGITM 
insert cups. The NGI was connected to a Copley HCP5 vacuum pump (Copley 
Scientific, United Kingdom). The flow rate was measured before every experiment and 
adjusted to 60 L/min, which models the flow rate of healthy adult lungs [34]. Glass fiber 
filters (55 mm, type A/E, Pall Life Sciences) were weighed and placed on the insert cups 
from stages 1 through 7 to reduce bounce or re-placement of powder [35]. 10 mg of 





Quali-V®, Qualicaps® Inc., Whitsett, NC, USA), and placed in a human dry powder 
inhaler (DPI) device (Handihaler, Boehringer Ingelheim Pharmacauticals, CT, USA). 
The DPI was then attached to a rubber mouthpiece connected to the NGI. Three capsules 
were released in every experiment (for a total of 30 mg) in triplicate. The NGI was 
operated with a delay time of 10s and running time of 10s. The particle deposition on 
each stage was determined gravimetrically by the difference in mass of the glass filter 
before and after particle deposition. The effective cutoff diameters for each impaction 
stage, at Q=60 L/min, were given by the manufactured as: Stage 1 (8.06 µm); Stage 2 
(4.46 µm); Stage 3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 (0.55 µm); 
and Stage 7 (0.34 µm). The fine particle dose (FPD), fine particle fraction (FPF), 
respirable fraction (RF), and emitted dose (ED) were calculated as follows: 
 





















The experimental mass median aerodynamic diameter (MMADE) and geometric 
standard deviation (GSD) for the particles were determined using a Mathematica® 
program written by Dr. Warren Finlay [35]. 
 
4.2.14.  Tapped density and theoretical aerodynamic size analysis of nCmP 
The density of nCmP was determined via tapped density measurements [36]. 25-
35 mg of particles (m) was weighed in a thin glass tube and tapped 200 times over a 
hard surface to ensure efficient packing. The height and diameter of compacted particles 
were measured using a digital caliper to calculate the volume occupied for the particles 












where d is the geometric diameter of nCmP determined by ImageJ and r* = 1 





4.2.15.  In vitro cell studies 
A549 human epithelial adenocarcinoma lung cancer cells were cultured in 
DMEM containing 10 v/v % FBS, 1 mM sodium pyruvate, 1 v/v % penicillin 
streptomycin (100 U/ml penicillin, 100 µg/ml streptomycin), and 0.2 v/v % Fungizone 
(0.5 µg/ml amphotericin B, 0.41 µg/ml
 
sodium deoxycholate). H441 cells were cultured 
in RPMI L-glutamine media containing same additives, except sodium pyruvate. Cells 
were incubated at saturated humidity, 37 °C, and 5% CO2. 
 
4.2.15.1.  Two-Dimensional (2D) cell culture and cell viability 
The viability of A549 cells exposed to PTX and PTX NP was evaluated using a 
resazurin assay on 2D cell monolayers. Cells (5,000 cells/well) were seeded in a flat 
bottomed 96-well plate and allowed to attach for 24 hours. PTX was dissolved in DMSO 
and then serially diluted in media (final DMSO concentration < 0.2 v/v%). Cells were 
dosed with raw PTX and PTX NP concentrations from 0.001 - 10 µM PTX and 
incubated for 48 hours. Resazurin was added to the wells (20 µL, 20 mM) and incubated 
for 4 hours prior to analysis. The fluorescence intensity was detected at 544/590 nm in 
a Cytation 3 plate reader (BioTek Instruments Inc., Winooski, VT, USA). Viability was 
expressed as relative viability of cells dosed with PTX formulations over control cells. 
 
4.2.15.2.  NP cellular uptake 
Confocal microscopy images were taken of A549 cells seeded on 35 mm glass 





Cells were exposed to 66 µM CUR NP and incubated for 3 hours, washed 3X with PBS, 
stained with CellMaskTM deep red plasma membrane (0.5 µL/mL in PBS), and fixed 
with 4% paraformaldehyde in PBS. Images were taken at 100X magnification. For 
quantification, A549 cells were seeded in flat bottomed 96-well plate (5,000 cell/well), 
incubated for 24 hours, and dosed with 66 µM CUR NP. After 3 hours of incubation, 
cells were washed twice with 200 mM glycine in PBS, twice with cold PBS, and finally 
fixed with 200-proof ethanol for 10 minutes. NP uptake was quantified using a 
fluorescence scan at 420/540 nm. 
 
4.2.15.3.  Transepithelial electrical resistance (TEER) evaluation 
Transepithelial electrical resistance was applied on an alveolar epithelium model 
cell line, H441 [37], to evaluate the integrity of the monolayer and tight junctions 
exposed to nCmP. 100,000 cell/well were seeded in the apical side of a 0.4 µm 
Transwell and grown in liquid covered culture for two days. Air interface culture was 
induced when media was removed from the apical side of the Transwells. TEER values 
were measured periodically until a tight monolayer was formed (stable TEER values), 
and Blank and PTX nCmP (1 mg/dose) in powder were dosed to the cells (day 0). TEER 
readings continued for five days and treated samples were compared to control cells.   





4.2.15.4.  Treatment of 3D multicellular spheroids (MCS) in liquid covered 
culture 
3D multicellular tumor spheroids (MCS) were formed via centrifugation using 
A549 cells for the evaluation of PTX formulations. 5,000 cells/well in media containing 
collagen type I (20 µL/mL cell solution) were seeded into ultra-low attachment round-
bottomed 96-well plates, centrifuged at 1100 g for 15 minutes, and incubated. At day 5, 
fully-formed MCS were dosed with raw PTX and PTX NP (5 – 0.001 µM PTX 
equivalencies), Blank NP, DMSO, and media (control). Bright-field images, using a 
Cytation 3 imager (BioTek Instruments Inc., Winooski, VT, USA), were taken at 
different time points over 15 days, and the diameter of MCS were recorded. The growth 
or inhibition of MCS upon PTX exposure was analyzed by calculating the change in 
size in treated MCS relative to untreated controls. 
 
4.2.15.5.  Treatment of 3D multicellular spheroids in air interface culture 
For the evaluation of PTX nCmP, cells were seeded into an alginate scaffold and 
grown in air interface culture (AIC) conditions. Alginate was purified as previously 
described [38] and stored in sterile conditions. 3 mL of 1.65 wt% alginate in PBS was 
loaded into a 5 mL syringe, and all bubbles were removed. In another 5 mL syringe, 750 
µL of 150 mM CaSO4 in PBS containing 1% (v/v) Fungizone was collected. The 
syringes were connected and vigorously mixed back and forth 5-8 times. The resulting 
mixture was transferred into spheroid micromolds from 3D Petri Dishes®  (5 x 7 array, 





the top, and gelation occurred at room temperature for 15-20 minutes.  Once the alginate 
scaffold had gelled, it was removed from the micromold and incubated overnight in 
DMEM prior to seeding.  The Young’s modulus of the alginate gels was determined 
using an Instron 3342 single-column apparatus (Norwood, MA) with a strain rate of 2 
mm/min until hydrogel failure. The Young’s modulus was calculated from the slope of 
the linear region of the resulting stress-strain curve using Instron’s Bluehill 3 software 
package. 
Alginate scaffold micromolds were placed in Transwell® inserts (3.0 µm pore 
size) for 12-well plates. 400 µL of DMEM was transferred to the basolateral 
compartment of the Transwell, and 75 µL of cell solution (1.33 x 106 cell/ml) was 
transferred to the scaffold (apical side). After MCS formation (day 1), media in the 
scaffold was gently removed to allow the MCS to grow in AIC conditions. Media from 
the basolateral side was replaced every other day. At day 5, ~ 1 mg of PTX nCmP was 
dosed onto the AIC MCS in powder form using a syringe and cone for dispersion. 
Images were taken periodically using the Cytation3 imager from days 1 to 12. The 
diameter of MCS treated with PTX nCmP were recorded and compared to untreated 
control. 
 
4.2.16.  Statistical analysis 
All measurements were performed in at least triplicate and values were 
presented as mean ± standard deviation. Half maximal inhibitory concentration (IC50) 





statistical significance of the results was determined using Student’s t-test, where p < 
0.05 (*) was considered statistically significant. 
 
4.3.  Results 
4.3.1.  Characterization of acetalated dextran (Ac-Dex) 
The synthesis of Ac-Dex resulted from the reaction between dextran and 2-MOP 
in the presence of an acid catalyst, and the resulting hydrophobic polymer contains both 
cyclic and acyclic acetal groups. NMR analysis of Ac-Dex showed a total acetal 
coverage (conversion of -OH groups) of 86% and a cyclic acetal coverage of 60%. 
 
4.3.2.  Nanoparticle characterization 
4.3.2.1.  Morphology, size, size distribution, and surface charge 
The size, distribution, and surface charge of NP are presented in Table 4.1. For 
PTX NP and Blank NP, the hydrodynamic diameters were less than 200 nm with low 
PDI (> 0.14) and slightly negative charges. PTX NP were spherical, as well as smooth 
and uniform dispersion as shown in Figure 4.1A. ImageJ size analysis from the SEM 
micrographs indicated smaller NP sizes of around 100 and 150 nm for PTX NP and 






Table 4.1  Characteristics of paclitaxel (PTX)-loaded nanoparticles (NP), blank NP 
without PTX, and PTX NP redispersed from PTX nanocomposite microparticles. 
Analysis includes NP diameter as measured by dynamic light scattering (DLS) and 
ImageJ, polydispersity index (PDI), zeta (ζ) potential, PTX loading in NP, and 


















198.4 ± 9.9 
103.6 ± 19.3 
0.14 ± 0.04 
N/A 
-3.14 ± 0.55 
N/A 
35.73 ± 1.56 71.5 ± 3.1 




191.9 ± 3.5 
150.3 ± 25.9 
0.12 ± 0.02 
N/A 
-4.79 ± 0.63 
N/A 
N/A N/A 




DLS 270.7 ± 11.0 0.34 ± 0.03 -18.47 ± 0.42 N/A N/A 








Figure 4.1  Representative scanning electron micrographs of nanoparticles (NP) and 
nanocomposite microparticles (nCmP) systems, and their in vitro paclitaxel (PTX) 
release profiles at different pH. (A) paclitaxel-loaded nanoparticles (PTX NP) at 
20,000X, (B) paclitaxel nanocomposite microparticles (PTX nCmP) at 5,000X, and (C)  
PTX nCmP at 40,000X. (D) Comparative release profiles of PTX from PTX NP and 
PTX nCmP at pH 7.4 and pH 5.1 (n = 3).	
 
4.3.2.2.  PTX loading and in vitro release 
PTX was encapsulated in Ac-Dex with an encapsulation efficiency of 71%, and 





release profile of PTX NP (Figure 4.1D) demonstrated steady, sustained release of 
PTX, with burst release around 10% for both pH values. At pH 7.4, the PTX release 
was slower, reaching 47% release in 7 days. In contrast, at pH 5.1 PTX release was 
faster, reaching a plateau at 48 hours with around 70% PTX release.  
 
4.3.3.  Nanocomposite microparticle characterization 
4.3.3.1.  Morphology, size, surface charge, and re-dispersion 
PTX nCmP exhibited wrinkled surfaces (Figure 4.1B), and formed raisin-like 
particles with visible nanoparticles (Figure 4.1C). The geometric diameter of nCmP, 
determined using ImageJ, was 2.17 µm (Table 2). PTX NP re-dispersed from PTX 
nCmP exhibited a slight increase in size to 270.6 nm, with a slightly higher PDI of 0.33, 
and a slightly more negative charge (-18.5 mV) (Table 4.1). 
 
4.3.3.2.  Drug loading, loading efficacy, and in vitro release from nCmP 
PTX nCmP had a drug loading of 3.04 wt% (30.38 µg PTX/mg of nCmP), 
corresponding to a PTX loading efficacy of 105 % in nCmP (Table 4.2). PTX nCmP 
exhibited sustained release of PTX at both pH values, with accelerated release in acidic 







Table 4.2  Characteristics of paclitaxel (PTX)-loaded nanocomposite microparticles 
(nCmP), including water content, PTX loading, nanoparticle (NP) loading in nCmP, NP 
loading efficacy in nCmP, geometric diameter (via Image J), tapped density, theoretical 
mass median aerodynamic diameter (MMADT), experimental MMAD (MMADE), and 





























(µm) GSD (µm) 
PTX nCmP 2.17 ± 0.59 0.33 ± 0.01 1.25 ± 0.01 2.44 ± 0.25 2.34 ± 0.42 
 
4.3.4.  Karl Fischer titration  
The residual water content of PTX nCmP was lower than 3% (Table 4.2), 
determined via colorimetric Karl Fischer Titration. 
 
4.3.5.  Solid-state analysis of particle formulations 
The DSC thermograms of raw materials and nCmP are shown in Figure 4.2A. 
Raw paclitaxel exhibited an endothermic phase transition peak at 222 °C and an 
exothermic peak at 243 °C. Raw Ac-Dex presented a broad endothermic peak around 
183°C and raw mannitol displayed a main phase transition peak at 171°C. Blank and 





were observed for any samples under 150 °C. Figure 4.2B presents powder X-ray 
diffractograms of raw materials and nCmP. Raw Ac-Dex presented no peaks, and raw 






 Figure 4.2  (A) Differential scanning calorimetry (DSC) thermograms and (B) powder 
X-ray diffractograms (PXRD) of raw paclitaxel (PTX), raw acetalated dextran (Ac-
Dex), raw mannitol, blank nanocomposite microparticles (nCmP) and paclitaxel-loaded 





4.3.6.  Density and theoretical MMAD of nCmP 
The tapped density and the theoretical mass median aerodynamic diameter 
(MMADT) of PTX nCmP are shown in Table 4.2. The corresponding values were 0.33 
g/cm3 and 1.25 ± 0.01 µm. 
4.3.7.  In vitro aerosol performance of nCmP 
The in vitro aerosol dispersion of PTX nCmP, evaluated in an NGITM, showed 
broad aerosol dispersion of particles across all stages, with 3% of the total mass 
depositing on the first stage, corresponding to a cutoff of 8.1 µm (Figure 4.3A). The 
majority of nCmP deposited on stage 4 (1.7 µm, 35%), with 4% depositing on at stage 
7 (0.34 µm). The experimental MMAD was 2.44 µm, with a GSD of 2.34 µm (Table 







Figure 4.3  In vitro aerosol dispersion performance of paclitaxel-loaded nanocomposite 
microparticles (PTX nCmP) in a Next Generation ImpactorTM (NGITM) for Q = 60 
L/min. (A) Particle deposition on each stage of the NGI, (B) Fine particle fraction (FPF), 








4.3.8.  In vitro cell analysis of PTX NP and PTX nCmP 
4.3.8.1.  In vitro cytotoxicity 
A 2D monolayer of A549 cells exposed to raw PTX and PTX NP exhibited a 




Figure 4.4  Two-dimensional (2D) cell culture evaluations including, (A) Cell viability 





NP (PTX NP) evaluated at 48 hours. (B) Cellular uptake of fluorescent curcumin-loaded 
nanoparticles (CUR NP) in A549 cells following 3 hours of incubation, including a 
representative confocal image showing CUR NP (green) and cell membrane (red), scale 
bar = 20 µm (Left) and fluorescence quantification of uptake (Right). (C) Transepithelial 
electrical resistance (TEER) analysis performed on H441 cells in air interface culture 
(AIC) conditions after exposure to blank and paclitaxel-loaded nanocomposite 
microparticles (Blank nCmP and PTX nCmP, respectively). Statistical analysis was 
performed using Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which 
represents the comparison to control (no exposure to nCmP) 
 
4.3.8.2.  Cellular uptake of CUR NP 
The cellular uptake of NP into 2D A549 cells was evaluated using fluorescent 
CUR NP with similar size, PDI, and surface charge to PTX NP. Figure 4.4B shows a 
representative confocal image of CUR NP associated in the cytoplasm of A549 cells, 
and the quantification of CUR NP uptake into the cells based on the fluorescence 
intensity of NP compared to control (cells only) after three hours of exposure. Overall, 
more CUR NP were successfully uptaken into A549 cells. 
 
4.3.8.3.  Transepithelial electrical resistance (TEER) evaluation 
The effect of PTX and Blank nCmP on cell monolayer integrity in air interface 
culture (AIC) conditions was evaluated via transepithelial electrical resistance (TEER). 





transitioning to AIC. The cells reached TEER values above 100 Ω cm2 a day after their 
transition from LCC to AIC conditions, and these values remained stable until analysis 
began (Figure 4.4C). During the first two days after exposure to the nCmP, cells 
exposed to Blank nCmP exhibited increased relative TEER, which then decreased 
slightly and was statistically the same as the control TEER. Cells exposed to PTX nCmP 
showed no statistical difference in TEER during the 5-day evaluation in comparison to 
the control. 
 
4.3.8.4.  LCC MCS growth inhibition evaluation  
3D A549 multicellular spheroids (MCS) in LCC dosed with raw PTX and PTX 
NP exhibited a dose dependent response in the inhibition of the growth of MCS in 
comparison to the control (Figure 4.5). In particular, MCS experienced growth 
inhibition when exposed to PTX concentrations equal to or above 0.01 µM. Figure 5C 
shows the comparison in the change of MCS diameter with respect to the control. 
Between 0.01 and 0.5 µM PTX MCS had similar responses to free PTX and PTX, where 
MCS size decreased with increasing PTX concentration. At higher concentrations (³ 1 
µM), MCS exposed to free PTX reached a plateau where size no longer decreased, and 







Figure 4.5  Analysis of multicellular spheroid (MCS) growth upon exposure to different 
concentrations of paclitaxel (PTX) formulations, including: (A) free PTX and (B) PTX 
NP. (C) Comparison of the change in diameter relative to control (media only) upon 
exposure to free PTX and PTX NP at day 15. Statistical analysis was performed using 
Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, which represents comparison 
with control (no exposure to PTX or PTX NP) in (A) and (B), and comparison between 






Figure 4.6 shows representative images of MCS dosed with 1 µM PTX at 
different time points, and their corresponding sizes. For days 1 and 5, the size of the 
MCS exposed to free PTX and PTX NP were similar to the control, whereas by day 15, 
MCS size decreased significantly upon exposed to free PTX and PTX NP. The effect of 
Blank NP on MCS growth was also evaluated, showing no significant difference to 
control MCS responses, with the exception of being slightly larger than the control MCS 




Figure 4.6  (Left) Representative bright-field images (scale bar = 500 nm) and (Right) 
corresponding quantification of A549 multicellular spheroid (MCS) growth upon 
exposure to 1 µM of free PTX, PTX nanoparticles (NP), and Blank NP equivalent to 1 
µM of NP in mass. Control MCS were exposed to media only. Statistical analysis was 
performed using Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which 






4.3.8.5.  AIC MCS growth inhibition evaluation 
The alginate micromold scaffolds exhibited a Young’s modulus of 3.55 ± 0.59 
kPa after 24 hours of incubation in DMEM. A549 cells seeded in the micromold were 
transitioned to AIC a day after seeding in LCC. At day 5, the spheroids were compact 
and fully formed (Figure 7A), and thus AIC MCS were exposed to nCmP at this time. 
Control MCS experienced continuous growth in AIC. After dosing with nCmP the 
surface of the MCS showed gradual disaggregation and tumor size reduction in 








Figure 4.7  Analysis of A549 multicellular spheroids (MCS) growth upon exposure to 
paclitaxel-loaded nanocomposite microparticles (PTX nCmP) in an 3D air interface cell 
culture (AIC) platform (scale bar = 500 µm). (A) Representative bright-field images of 
control and MCS exposed to PTX nCmP. (B) Quantification of MCS exposed to PTX 
nCmP in comparison to control (media only). Statistical analysis was performed using 
Student’s t-test (p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which represent the 
comparison to control, no exposure to PTX nCmP) 
 
4.4.  Discussion 
Water-soluble dextran was transformed to hydrophobic Ac-Dex during the 5-
min reaction, where the -OH groups were converted into acetals. Ac-Dex had a high 
total -OH conversion (86%) that can ensure the stability of particles and allow for the 
formation of small NP (when >75%) [36]. The formation of acetals, quantified by -OH 
conversion and cyclic acetal conversion (60%), allows the NP to have pH-tunable 
degradation for drug delivery into acidic tumors or inflammatory tissues [39].   
The small size of PTX NP reported from the SEM micrographs and ImageJ (104 
nm) represent NP size in their dry state. The hydrodynamic size of PTX NP was 
evaluated with DLS, showing sizes around 200 nm; this technique allows measurement 
of NP size with a hydrated layer. PTX NP had a low PDI, resulting in high stability in 
an aqueous suspension due to the steric effect of PVA coating [40]. SEM images of NP 
corroborates the high homogeneity reached with single emulsion fabrication. After 





diameter, likely due to agglomeration during the spray drying process, which is 
confirmed by a higher PDI (0.33). The slightly more negative charge of re-dispersed 
PTX NP can be attributed to mannitol in the formulation, which showed a charge of 
around -19.23 mV in water solution, compared to the almost neutrally-charged PTX NP.  
The in vitro PTX release profiles of the NP and nCmP were evaluated in 
physiological (pH 7.4) and acidic (pH 5.1) conditions. The systems exhibited burst 
releases below than 13%, which is an essential characteristic for optimal extended-
release delivery systems [41]. The release profiles at each pH were similar between the 
NP and nCmP. In acidic conditions, 70-80% of PTX was released after 48 hours, which 
can be favorable for the release of the drug in the acidic microenvironments of cancer 
cells. At pH 7.4, PTX release was slower, reaching 50% release after 7 days, which may 
be beneficial to avoid high concentrations of chemotherapeutic when the particles 
deposit in healthy tissue. 
PTX NP exhibited high PTX encapsulation efficiency (71% corresponding to 
35.7 µg PTX/mg NP), and after spray drying the PTX loading in nCmP was 30.4 µg 
PTX/mg nCmP, which corresponds to a NP loading efficiency in nCmP above 100%. 
This phenomenon is likely due to the loss of PVA from the NP during the spray drying 
process, which leads to an increase in the percentage of PTX in the total mass of 
particles. Overall, both the NP and nCmP successfully encapsulated PTX. The low 
water content in PTX nCmP, determined using colorimetric Karl Fisher, can enable 
storage stability of the particles, and can prevent agglomeration during aerosolization.   
DSC analysis was performed for raw materials and nCmP to evaluate their 





decomposition peak at 243°C (evident for raw PTX) in PTX nCmP suggests that 
amorphization of the drug occurred during spray drying or that the amount of PTX in 
the nCmP was below the detection limit for DSC. The strong peak from pure mannitol 
was slightly shifted for the nCmP, appearing around 158°C. The other broad peak 
present for nCmP is likely due to displacement of the Ac-Dex phase transition peak. 
Overall, nCmP showed temperature stability under 150°C for manufacturing and 
storage conditions.  
The crystallinity of raw materials and nCmP were analyzed by PXRD. The lack 
of peaks in the Ac-Dex diffractogram indicate that it is an amorphous polymer, which 
likely because of the rapid precipitation method of collection after the Ac-Dex reaction. 
While raw PTX and mannitol exhibited strong peaks and are thus crystalline, these 
peaks are no longer present in nCmP. This indicates the likelihood of amorphization of 
PTX and mannitol after the spray drying process. These data agree with the reduced and 
transformed peaks observed in DSC analysis. Reduced crystallinity of the nCmP 
formulation is advantageous for the rapid solubilization of nCmP formulations (and thus 
PTX) after delivery to the lungs. 
The in vitro aerosol performance of PTX nCmP was conducted using a Next 
Generation ImpactorTM coupled with a human DPI device. The simulated inhalation 
resulted in a high emitted dose of particles (88%), which is necessary to make use of the 
most of each capsule. The fine particle fraction of PTX nCmP demonstrates that 66% 
of the nCmP mass released from the capsules had a particle size lower than 4.4 µm, and 
that 97% of the particles deposited in the NGI (respirable fraction) demonstrate the 





that deposited on the first stage (3%) deposited primarily by impaction (≥ 5 µm) [12]. 
Particles that deposited in stage 2 to 6, corresponding to 93% to the total mass in all 
stages of the NGI, would likely be able to deposit in the lungs due to sedimentation, and 
the smaller particles (< 0.5 µm) from stage 7 would likely deposit via Brownian motion 
[11]. The high dispersion of nCmP (GSD of 2.34 µm) demonstrate the ability of nCmP 
to deposit in all stages of the NGI. 
The theoretical mass median aerodynamic diameter (MMADE) was calculated 
from the geometric diameter from SEM micrographs and tapped density of the PTX 
nCmP, and the MMADE (1.25 µm) was smaller than the experimental MMAD (2.44 
µm) obtained using a NGI. The increase in MMAD during aerosolization in the NGI is 
likely due to agglomeration of the particles due to ambient humidity and the electrostatic 
effect of particles with each other and the DPI device [42], which can increase the 
deposition in the upper airways [43]. The deposition of the PTX nCmP in lower stages 
was likely achieved because of their low tapped density, which can be attributed to the 
raisin-like morphology of the nCmP. The hollow shell morphology of the nCmP can be 
attributed to the saturation of NP at the droplet surface compared to the droplet center, 
where NP diffusion is slower than the surface shrinkage during spray drying. As the 
evaporation process occurs, the droplet shell collapses and wrinkled particles with low 
density are formed [44], as observed in the PTX nCmP.  
The cytotoxicity of raw PTX and PTX NP was evaluated in LCC 2D and 3D cell 
culture models. 2D A549 cells were dosed with raw PTX and PTX NP and there was a 





exposure, suggesting that the sustained release of the drug plays a role in the enhancing 
cell death [41].  
For cellular uptake, CUR NP were selected for their similar size and charge to 
PTX NP and the ease in imaging fluorescent CUR. Since NP surface charge is nearly 
neutral, the main parameter that can influence NP internalization in cells is their size. It 
was previously reported that 100-200 nm polymeric NP might be the optimal size for 
the highest uptake in cells and to avoid alveolar macrophage clearance [45]. CUR NP 
were successfully uptaken into the A549 cytoplasm after three hours of exposure, 
indicating the NP have the potential to deliver and release PTX directly inside the cells. 
In order to determine the effects of Blank and PTX nCmP on the lung 
epithelium, we evaluated the integrity of the tight junctions of a monolayer of H441 
cells upon exposure to nCmP via transepithelial electrical resistance (TEER) 
measurements. H441 cells were grown in a 2D monolayer as a human distal lung 
epithelial model [46], and following growth in AIC, were dosed with nCmP powders. 
Cells exposed to Blank nCmP showed increased TEER two days after exposure, and 
after a decrease on day 3, they showed no difference to control cells. The increase in 
TEER upon Blank nCmP exposure is likely due to exposure of the cells to the by-
product dextran following the degradation of Ac-Dex as nutrient for the cells. Cells 
exposed to PTX nCmP did not show significant reduction in TEER for up to 5 days of 
exposure, suggesting a conservation in the tight junctions in the monolayer of cells and 
potential safety of the formulation. 
While 2D cell culture has been extensively used for drug screening, a 3D 





vitro due to their similar structures, physiological responses, cell-drug interactions, and 
drug resistance mechanisms [47, 48]. MCS grown in a 3D LCC model were dosed with 
free PTX and PTX NP 5 days after MCS formation. MCS at this point were considered 
to be fully developed spheroids with heterogenous structure: a proliferating region, a 
quiescent viable region, and a necrotic core. This phenomenon has been confirmed in 
our previous work and is in accordance with other reports where MCS > 200 µm 
(usually > 4 days of growth) have shown similar morphology to real tumors [26, 28]. 
MCS growth lasted for 15 days, since after this point control MCS size begins to decline.  
PTX NP showed no clear superiority in the inhibition of MCS growth in 
comparison to free PTX, except at higher concentrations (³ 1 µM), implying that PTX 
NP were capable of delivering PTX more effectively to and/or penetrating MCS, in 
comparison to free PTX. The likelihood of limited penetration in the MCS is supported 
by the fact that solid tumors develop a dense extracellular matrix (ECM) that prevents 
the transport and diffusion of large molecules into the tumor interstitial space [49, 50]. 
Collagen, one of the main components in ECM, is known to increase the resistance to 
interstitial transport in tumors [51]. The LCC MCS produced via centrifugation for this 
project contained type I collagen to facilitate the agglomeration of cells and reproduce 
ECM in the MCS. The formation of the solid external cell layer in the spheroids was 
visible in the bright-field images when they changed from loose aggregates of cells to 
solid tumor spheroids from day 1 to day 5 (Figure 4.6). Finally, Blank NP showed no 
toxic effects or alterations in the normal growth of the MCS, likely due to the MCS 
exposure to the harmless degradation by-products of Ac-Dex, which can cause an 





To demonstrate proof-of-concept treatment of lung cancer via aerosol delivery 
of PTX-loaded dry powders, PTX NP were spray dried with mannitol to obtain (nCmP), 
which are designed to be delivered using a dry powder inhaler. To evaluate the 
chemotherapeutic effect of the particles, MCS grown in an alginate micromold at air 
interface culture (AIC) conditions were dosed with dry powder PTX nCmP. The 
alginate scaffold exhibited similar stiffness to that of lung tissue, which has a Young’s 
modulus between 1 and 5 kPa [52]. 5 days after a treatment, the MCS size decreased 
significantly, and this reduction and disaggregation of cells were signal of cell death 
promoted by PTX delivered from the NP. AIC MCS were developed and characterized 
in our previous work [38]. For this project, PTX nCmP were evaluated using AIC MCS, 
and this cell culture platform can serve for future evaluations of dry powder 
formulations as a more accurate representation of pulmonary conditions. Overall, PTX 
nCmP show promise in the treatment of lung cancer via a pulmonary route. PTX nCmP 
have the potential to reduce the total dose administered and reach the targeted site of the 
disease in comparison to systemic delivery. 
 
4.5.  Conclusions 
We developed a paclitaxel-loaded aerosol nanocomposite microparticle (PTX 
nCmP) formulation based on spray-dried Ac-Dex PTX-loaded NP and mannitol. PTX 
nCmP exhibited favorable distribution and deposition in in vitro aerosolization using an 
NGI, with a size and morphology that can allow them to reach the alveoli region. NP 
were successfully re-dispersed from nCmP upon contact to aqueous medium. The 





were highly affected by PTX NP is comparison to free PTX, however, this correlation 
was not seen in the 3D LCC model. In this case, PTX NP impacted MCS growth 
inhibition more significantly only at high PTX concentrations when compared to free 
PTX. This phenomenon demonstrates the complex interaction of nanoparticles with 
MCS. The 3D AIC platform aided in the assessment of PTX nCmP, showing its 
potential as an in vitro model to better mimic pulmonary environments and promoting 
its further application in the evaluation of other dry powder formulations intended to be 
delivered via a pulmonary route. Overall, the described work involves a new nCmP 
platform capable of effectively delivery PTX to lungs via their aerosolization as a dry 
powder. 
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Mucus is an adhesive hydrogel that represents one of the major barriers for 
successful inhaled treatments. The development of nanoparticles (NP) capable of mucus 
penetration is desired for the treatment of a variety of pulmonary diseases, and there is 
a need for effective particle deposition in the lungs. The objective of this study was to 
develop and evaluate the mucus-penetrating ability of PEGylated nanocomposite 
microparticles (nCmP) intended to be delivered via a dry powder inhaler. Poly(vinyl 
alcohol) (PVA) and vitamin E poly(ethylene glycol) (VP5k)-coated polymeric 
nanoparticles were synthesized via single emulsion and nanoprecipitation, respectively, 
using acetalated dextran, a biodegradable polymer. Both formulations resulted in 
spherical, smooth, highly homogeneous NP with diameters of ~200 nm and a slightly 
negative surface charge. nCmP were produced via spray drying, and showed optimal 
size and aerosol distribution for targeted pulmonary deposition based on the 
formulation, as evaluated by a Next Generation ImpactorTM. The mucus penetration of 
nanoparticles was assessed using a Transwell® diffusion chamber, where 33 % more 
NP permeated through artificial mucus when coated with VP5k compared to PVA 
nanoparticles. The combination of the potential for targeted deposition in the lungs 
using mucus-penetrating nCmP represents a potential advantage in the improvement of 
therapeutic nanomedicines delivered via a pulmonary route. 
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CUR, curcumin; NP, nanoparticles; Ac-Dex, acetalated dextran; VP5k, vitamin 
E poly(ethylene glycol); PVA, poly (vinyl alcohol); CAC, cyclic acetal coverage;  
PPTS, pyridinium p-toluenesulfonate; DMSO, dimethyl sulfoxide; 2-MOP, 2-
methoxypropene; TEA, triethylamine; DCM, dichloromethane; PBS, Phosphate 
buffered saline (1X PBS dilution unless specified); AM, artificial mucus; DCC, N-N 
dicyclohexylcarbodiimide; DMAP, 4-dimethylaminopyridine; DNA, Deoxyribonucleic 
acid; NMR, nuclear magnetic resonance; DLS, dynamic light scattering; PDI, 
polydispersity index; DL, drug loading; EE, encapsulation efficacy; DSC, differential 
scanning calorimetry; PXRD, powder X-ray diffraction; KF, Karl Fischer titration; NGI, 
next generation impactor; MMADT, theoretical median aerodynamic diameter; 
MMADE experimental median aerodynamic diameter; GSD, geometric standard 
deviation; FPD, fine particle dose; FPF, fine particle fraction; RF, respirable fraction; 
ED, emitted dose; DPI, dry powder inhaler; Fc, feed concentration; CF, cystic fibrosis. 
 
5.1.  Introduction 
Pulmonary delivery is an attractive route for the delivery of therapeutics to the 
lungs, as higher amounts of drug can reach the site of disease, thus reducing the overall 
dose required, compared to systemic delivery [1]. In recent years, aerosol 
nanomedicines have been studied for the treatment of local pulmonary diseases such as 
lung cancer [2], cystic fibrosis (CF) [3], and pulmonary hypertension [4], among others. 
While offering many advantages, the pulmonary route also presents physiological and 





[5]. Some of the main parameters needed to ensure effective targeting and delivery of 
therapeutics into the lungs include: (i) deposition and localization of therapeutics, (ii) 
escape from mucociliary clearance, and (iii) penetration through mucus in the airways 
[6].  
Aerosol deposition in the lungs is governed by the aerodynamic diameter of 
particles, and occurs by one of the following mechanisms: inertial impaction (≥ 5 µm), 
sedimentation (0.5–5 µm), or diffusion (< 0.5 µm) [7, 8]. Nanoparticles (NP) deposit in 
the lungs by diffusion due to Brownian motion, and deposition can be enhanced by 
breath holding (reduction of airflow); however, they can also be easily exhaled. 
Aggregates of nanoparticles can be designed to have enough mass for effective 
pulmonary deposition, and can dissociate back into nanoparticles once deposited in the 
lungs [9, 10], thereby overcoming the deposition barrier. 
In the upper airways, the epithelium is covered by mucus that is produced by 
goblet cells. This mucosal barrier provides protection for the epithelium against 
chemical and mechanical damage, preventing the penetration of pathogens and toxins, 
and regulating the moisture content of the tissue beneath [11, 12]. Mucus is a viscous 
gel layer composed mainly of water (95-99 wt%), and a complex mixture of salts, lipids, 
nucleic acids, macromolecules, and glycoproteins called mucins, which form a 
crosslinked and entangled mesh fiber of mucins that confer a negative charge to the 
mucus due to their carboxyl and sulfate groups [13-15]. This dense fiber mesh traps, 
immobilizes, and removes larger particulates and particles with adhesive and steric 
interactions, and is followed by mucociliary clearance to remove the particles from the 





from 100 - 500 nm in healthy lungs [18], and 60 - 300 nm in sputum of people with CF 
[19]. Mucus has a neutral pH (7.0) and its thickness in the pulmonary airways may range 
from 5-55 µm, with a turnover of 10-20 min  [20].  
The challenges involved in designing nanomedicines capable of effective 
pulmonary delivery has resulted in a strong interest in developing formulations that can 
overcome barriers such as mucus. Strategies such as surface modification of 
therapeutics using PEGylation [21], as well as the use of muco-inert biomaterials such 
as polysarcosine and mucolytic agents such as papain [16, 22] have extensively been 
investigated to enhance the mucus penetration of therapeutics. For example, NP with 
diameters up to 200 nm that were densely coated with PEG (3.4 kDa) moved through 
undiluted CF sputum [19]. In another study, 5kDa PEG-coated NP (≤ 300 nm) exhibited 
uniform distribution and retention in mucus compared to non-PEGylated NP. [23]. 
While size seems to be relevant in the ability of NP to penetrate mucus, the NP coating 
will ultimately determine their permeability through the mucus mesh. For NP that have 
been PEGylated, the hydrophilic and near-neutrally charged surface provides shielding 
of the particle surface to reduce hydrophobic or electrostatic interactions with mucus 
[24]. Furthermore, PEGylation contributes to the colloidal stability of nanoparticles 
[25]. A moderate PEG density coating (up to 5 kDa) favors NP  penetration into mucus, 
however, a very high PEG density coating (≥ 10 kDa) can transform NP into 
mucoadhesive agents [26]. 
The development of mucus penetrating particles capable of overcoming the 
mucus barrier and efficiently depositing in the lungs upon aerosolization represents an 





formulated and evaluated the mucus penetrating capabilities of NP coated with vitamin 
E poly(ethylene glycol) (VP5k) and encapsulated in nanocomposite microparticles 
(nCmP) for effective lung deposition using a dry powder inhaler. Fluorescent NP were 
formulated using curcumin, which was loaded in the biodegradable polymer, acetalated 
dextran (Ac-Dex) [27, 28]. NP were coated with poly(vinyl alcohol) (PVA), a widely 
used surfactant in NP formulations, and VP5k, a PEG-based compound reported to have 
mucus penetrating properties [29]. Following NP formation, mucus penetration studies 
were carried on artificial mucus (AM). nCmP were formulated via spray drying, and 
following evaluation using a Next Generation Impactor, the nCmP showed the potential 
to deposit in the upper airways and lower regions of the lungs. Upon deposition, NP can 
be re-dispersed and penetrate the mucosal layer based on the coating provided. The 
improved penetration and effective deposition of particles in specific regions in the 
lungs can lead to a more personalized treatment for patients having different diseases 
and can help to overcome some of the challenges associated with pulmonary delivery. 
 
5.2.  Materials and Methods 
5.2.1.  Materials 
Dextran from Leuconostic mesenteroides (MW 9,000-11,000), pyridinium p-
toluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), 2-
methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥ 99%), deuterium chloride 
(DCl, 35 wt% in D2O, 99% atom D) solution, dichloromethane (DCM, > 99.8%), 
anhydrous sodium acetate, D-mannitol (≥98%), D-α-tocopherol succinate, 1210 IU/g 





dicyclohexylcarbodiimide (DCC, 99%), deoxyribonucleic acid sodium salt from salmon 
testes (DNA), mucin from porcine stomach type II, RPMI 1640 amino acid solution 
without L-glutamine, and potassium chloride (KCl, 99.0-100.5%) were obtained from 
Sigma-Aldrich (Natick, MA, USA). Deuterium oxide (D2O, 99.8% atom D), 
chloroform-d for NMR (99.8 atom % D), poly(vinyl alcohol) (PVA, 87-89% 
hydrolyzed, MW 13,000 – 23,000), 4-dimethylaminopyridine (DMAP, 99%), and 
curcumin (CUR, > 98%) were obtained from Acros Organics (Geel, Belgium). 
HydranalTM Coulomat, sodium chloride (NaCl), and agar were obtained from Fisher 
Scientific (Somerville, NJ, USA). Phosphate buffered saline (PBS) was obtained from 
Research Products International (RPI) (Mount Prospect, IL, USA). Egg yolk emulsion 
(50% solution) was purchased from Dalynn Biologicals (Calgary, Alberta, Canada). 
HyPure TM molecular biology grade nuclease-free water was purchased from GE 
Healthcare Life Sciences (Logan, Utah, USA). 
 
5.2.2.  Synthesis of Acetalated Dextran  
The synthesis of 3-hour acetalated dextran (3-hour Ac-Dex, Figure S1) was 
conducted as previously described [30] with some modifications. 1 g of lyophilized 
dextran and 35 mg of PPTS were dissolved in anhydrous DMSO under N2. The reaction 
was initiated by the addition of 7.5 ml of 2-MOP, and lasted for 3 hours, followed by 
quenching with 1 ml TEA. The product was then precipitated in basic water, frozen 





5.2.3.  Synthesis of Vitamin E Poly(ethylene glycol)  
m-PEG was conjugated to vitamin E following a previously described method 
with some modifications [29, 30]. Vitamin E succinate (1.95 g) and m-PEG (22 g) were 
dissolved in 60 mL of DCM for 45 min. Then DMAP (45 mg) and DCC (0.84 mg) were 
added to the solution for overnight reaction at room temperature (Figure S2A). The 
reaction mixture was vacuum filtered (0.45 µm), and was concentrated under reduced 
pressure using a rotor vapor (IKA, RV, Wilmington, NC, USA) to obtain crude product, 
which was dissolved at 5% (w/v) in ultrapure water to eliminate excess solvent and 
unreacted vitamin E succinate. The diluted crude product was centrifuged twice (19,802 
rcf, 30 min), from which the supernatant was collected, filtered (0.22 µm), frozen, and 
lyophilized for 72 hours.  
 
5.2.4.  Nuclear Magnetic Resonance Analysis of Acetalated Dextran and Vitamin 
E Poly(ethylene glycol) 
The total acetal coverage (conversion of hydroxyl groups) and type of acetals 
formed in Ac-Dex was determined by 1H-NMR spectroscopy (Bruker 300 MHz NMR, 
MA, USA). 10 mg of Ac-Dex was suspended in 700 µL of D2O and was then hydrolyzed 
with 30 µL of DCl in an NMR tube. The hydrolysis of acyclic acetals produces methanol 
and acetone whereas cyclic acetals produce only acetone. The total acetal coverage and 
the cyclic acetal coverage (CAC) were determined after normalization of the methanol 





with the number of protons detected on each molecule. The results were expressed per 
100 molecules of glucose.  
The conjugation of mPEG to vitamin E succinate was confirmed by 13C NMR 
(NMRS 500 MHz spectrometer, Agilent Technologies Santa Clara, CA, USA). 20 mg 
of vitamin E succinate or VP5k was diluted in 700 µL of CDCL3 and analyzed to obtain 
their respective spectrograms. The shift of the peak from vitamin E at 178 ppm 
corresponding to -COOH to 172 ppm (-COO-CH2-) in VP5k confirmed successful 
conjugation.  
 
5.2.5.  Preparation of Curcumin-Loaded Ac-Dex Nanoparticles coated with PVA 
and VP5k 
Curcumin (CUR)-loaded nanoparticles coated with PVA (PVA CUR NP) were 
prepared via single emulsion and solvent evaporation. The organic phase was comprised 
of 1.25 mg of CUR and 48.75 mg of Ac-Dex dissolved in 1 ml DCM, and the aqueous 
phase contained 3% PVA in PBS to result in an initial loading of 2.5 wt% CUR. 6 mL 
of 3% PVA in PBS was added to the organic phase and sonicated (Q500 Sonicator, 
Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off pulse at an amplitude 
of 70% (100% amplitude = 120 µm). The emulsion was added to 0.3% PVA in PBS, 
allowed to spin for 4 hours (340 rpm), collected, washed via centrifugation (1X), and 
re-dispersed in 0.1% PVA in DI water before freezing and lyophilization. CUR-loaded 
nanoparticles coated with VP5k (VP5k CUR NP) were made via nanoprecipitation. 1 





min. The solution was injected dropwise using a 30G needle into a 40 ml 3% VP5k 
solution in PBS. After 3-4 hours of spinning (340 rpm), the NP were filtered (0.45 µm), 
washed via centrifugation 1X, re-dispersed in 0.5% VP5k in DI water, and frozen and 
lyophilized. 
  
5.2.6.  Formulation of Curcumin Nanocomposite Microparticles (CUR nCmP) via 
Spray Drying 
CUR-loaded nCmP were formulated with CUR NP and mannitol in an aqueous 
suspension using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, Switzerland) in 
open mode. The ratios of CUR NP: mannitol was 70:30 (w/w) in DI water at a feed 
concentration (Fc) of 1.5% (w/v) and 100:0 at a Fc = 0.5% (w/v). The spray dryer 
conditions were: 414 L/h dry N2 flow rate, aspiration rate of 28 m3/h, pump rate of 0.9 
mL/min, nozzle cleaner rate of 4, inlet temperature of 55 °C for PVA coated NP, and 
50 °C for VP5k coated NP. The nCmP were collected in amber glass vials and stored in 
desiccators at -20 °C. 
 
5.2.7.  Particle Morphology and Shape Analysis via Scanning Electron 
Microscopy  
The surface morphology and shape of the NP and nCmP were evaluated by 
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning 
Electron Microscope (Germany). NP were suspended in basic water (10 mg/ml), 





placed on SEM stubs covered by double-sided adhesive carbon tabs. Samples were 
sputter coated with a thin film of gold/palladium alloy in a BIO-RAD system at 20 µA 
for 15 seconds under argon gas. Images were captured at 5 kV and various 
magnifications. 
 
5.2.8.  Particle Size, Size Distribution, and Zeta Potential Analysis of 
Nanoparticles 
The hydrodynamic size, size distribution (polydispersity index, PDI), and zeta 
potential of parent NP and NP re-dispersed from nCmP were measured by dynamic light 
scattering (DLS) using a Malvern Nano Zetasizer (Malvern Instruments, 
Worcestsershire, UK). The nanoparticles were suspended in basic water (0.5 mg/mL, 
pH 9), vortexed, and sonicated for one minute. All measurements were performed at 
25°C. 
 
5.2.9.  Analysis of CUR Loading in NP and nCmP 
Samples of NP and nCmP were dissolved in DMSO (0.2 mg/ml) and CUR 
content was analyzed using fluorescence spectroscopy at 420/540 nm in a Biotek 
Cytation 3 microplate reader (BioTek Instruments Inc., Winooski, VT, USA). CUR 
concentration was quantified by comparison with a standard calibration curve of CUR 
in DMSO. CUR loading and encapsulation efficacy in the particles were calculated 
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5.2.10.  In Vitro Drug Release from NP and nCmP 
The in vitro release of CUR from NP and nCmP was determined via a release 
study of suspended particles (1 mg/mL, 1.8 mL) in modified phosphate buffer (PBS, 0.1 
M, pH 7.4, 0.5% wt% Tween 80) and modified acetate buffer (0.1 M, pH 5, 0.5% wt% 
Tween 80). Particle suspensions were incubated at 37°C and 100 rpm (Digital Heat 
Block and Orbi shaker, Benchmark Scientific, Edison, NJ, USA). At various time points 
(0-5 days), particle samples were centrifuged at 23,102 rcf for 5 min at 4°C to isolate 
the NP. 200 mL of supernatant was withdrawn and replaced by the same amount of 
fresh buffer. Supernatant samples were dissolved in 200 µL DMSO and analyzed for 
CUR content by fluorescence spectrometry as described previously.  
 
5.2.11.  Solid-State Analysis of NP and nCmP 
The thermal phase transitions of NP, nCmP, and raw materials were determined 
by differential scanning calorimetry (DSC) using a TA Q10 DSC system (TA 
instruments, New Castle, DE, USA) equipped with an automated computer-controlled 





pans and hermetically sealed. The sealed sample pan was placed in the DSC chamber 
along with an empty sealed reference pan, which were heated from 0-260 °C at a rate 
of 10 °C/min. Powder x-ray diffration (PXRD) was applied to determine the crystalline 
states of nCmP and its raw components using a Rigaku Multiflex X-ray diffractometer 
(The Woodlands, TX, USA) with Cu Ka radiation source (40KV, 44mA). The samples 
were placed in a horizontal slit holder prior to analysis. The scan range was 5-60 ° in 2q 
with a sampling width of 0.1 and scan speed of 1°/min. 
 
5.2.12.  Karl Fischer Coulometric Titration  
The water content in nCmP was quantified by Karl Fischer (KF) coulometric 
titration using a 737 KF coulometer (Metrohm, Riverview, FL, USA). 10 mg of particles 
were dissolved in a known mass of anhydrous methanol and injected into the reaction 
cell filled with Hydranal® KF reagent. The water content was analyzed and reported in 
wt%. Pure solvent was analyzed as background sample.  
 
5.2.13.  nCmP In Vitro Aerosol Dispersion Performance with a Next Generation 
Impactor  
The in vitro aerosol dispersion of dry powder nCmP was evaluated using a Next 
Generation ImpactorTM (NGITM, MSN Corporation, Shoreview, MN, USA) equipped 
with a stainless-steel induction port attachment (USP throat) and gravimetric NGITM 
insert cups. The NGI was connected to a Copley HCP5 vacuum pump (Copley 





adjusted to 60 L/min, which models the flow rate of healthy adult lungs [31]. Glass fiber 
filters (55 mm, type A/E, Pall Life Sciences) were weighed and placed on the insert cups 
from stage 1 through 7 to reduce bounce or re-placement of powders [32]. 10 mg of 
powder was loaded into a hydroxypropyl methylcellulose capsule (HPMC, size 3, 
Quali-V®, Qualicaps® Inc., Whitsett, NC, USA) and placed in a dry powder inhaler 
(DPI) device (Handihaler, Boehringer Ingelheim Pharmacauticals, CT, USA). The DPI 
was then attached to a rubber mouthpiece connected to the NGI. Three capsules were 
released in every experiment (for a total of 30 mg) in triplicate. The NGI was operated 
with a delay time of 10s and running time of 10s. The particle deposition on each stage 
was determined gravimetrically by the difference in mass of the glass filter before and 
after deposition. The effective cutoff diameters for each impaction stage, at Q = 60 
L/min, were given by the manufacturer as: Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage 
3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 (0.55 µm); and Stage 7 (0.34 
µm). The fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF), 
and emitted dose (ED) were calculated as follows: 
 





















The experimental mass median aerodynamic diameter (MMADE) and geometric 
standard deviation (GSD) for the particles were determined sing a Mathematica® 
program written by Dr. Warren Finlay [32]. 
 
5.2.14.  Tapped Density and Theoretical Aerodynamic Analysis of nCmP 
The density of nCmP was determined via tapped density measurements [33]. 25-
35 mg of particles (m) was weighed in a thin glass tube and tapped 200 times over a 
hard surface to ensure efficient packing. The height and diameter were measured using 
a digital caliper to calculate the volume occupied for the particles (V). The tapped 















where d is the geometric diameter of nCmP determined by ImageJ and  r* = 1 
g/cm3 is the reference density of solid polymer. 
 
5.2.15.  Preparation of Artificial Mucus 
Artificial mucus (AM) was prepared following a previously described protocol 
[34], where 500 mg DNA, 250 mg mucin, 0.295 mg DPTA, 250 mg NaCl, 110 mg KCl, 
1 mL RPMI 1640 amino acid solution, and 250 uL egg yolk emulsion were added to a 
final volume of 50 mL of DNase-free water. The mixture was stirred for 2 hours at room 
temperature to allow stabilization, and was used within 48 hours.  
 
5.2.16.  Analysis of Freeze-Dried Artificial Mucus Morphology  
Fresh artificial mucus was plated in a 24-well plate, flash frozen in liquid 
nitrogen, and lyophilized. Transverse slices of lyophilized AM were placed on 
aluminum SEM stubs with double-sided adhesive carbon tabs. The samples were coated 
an imaged via SEM as previously described. 
 
5.2.17.  Evaluation of Nanoparticle Penetration through Artificial Mucus 
The mucus penetration of NP and free CUR in AM was evaluated as follows. A 
0.3% (w/v) agar solution (500 µL) was placed in the bottom a 12-well plate and 
hardened at 4°C. A Transwell® (3.0 µm pore size) for 12-well plates (Corning Life 





placed in the apical side. Free CUR was dissolved in DMSO (3.68 mg/mL) and diluted 
in DI water for a final DMSO concentration of 5% (v/v). NP formulations were 
suspended in DI water. All formulations had a CUR concentration of 500 µM. 100 µL 
of each CUR formulation (free CUR, PVA CUR NP, or VP5k CUR NP) was placed on 
top of the AM in the Transwell® and the Transwell was moved to a new well with fresh 
agar at different time points. At the end of the test, the agar was melted and dissolved 
in 350 µL of DMSO. The CUR concentration in the samples from the basolateral side 
of the Transwell® (agar) was determined via fluorescence spectrometry. The results 
were reported as CUR permeated (µg) over time for the different formulations. 
 
5.2.18.  Statistical Analysis 
The measurements were performed in at least triplicate. All values were 
presented as mean ± standard deviation.  The statistical significance of the results was 
determined using Student’s t-test and ANOVA for the mucus penetration study, where 
p < 0.05 was considered statistically significant. 
 
5.3.  Results 
5.3.1.  Characterization of Ac-Dex and VP5k 
The 3-hour reaction between dextran and 2-MOP in the presence of PPTS 
resulted in the synthesis of acetalated dextran (Ac-Dex), which contains both cyclic and 





coverage (conversion from –OH groups) of 83% and a cyclic acetal coverage of 90%. 
Vitamin E succinate was conjugated to m-PEG 5k and confirmed by 13C NMR, as can 
be observed in the spectrograms in Figure B.2B. The carbonyl carbon peak at 178 ppm 
(-COOH) from vitamin E shifted to a carbonyl carbon at 172.1 ppm (-COO-CH2) in 
VP5k due to the reaction. The second carbonyl at 171 ppm and aromatic carbons from 
150 ppm to 115 ppm remained the same in both compounds and finally an intense peak 
at 70.5 ppm appeared in VP5k, corresponding to the -OCH2 from m-PEG. 
 
5.3.2.  Nanoparticle Characterization 
5.3.2.1.  Morphology, Size, Size Distribution, and Surface Charge 
The sizes, distribution, and surface charges of parent and re-dispersed NP are 
presented in Table 5.1. The hydrodynamic size of PVA CUR NP was around 180 nm 
with low PDI (0.13) and slightly negative charge (-2.51 mV). PVA CUR NP exhibited 
spherical, smooth morphology and uniform dispersion (Figure 5.1A). VP5k CUR NP 
exhibited diameter, PDI, and surface charge values of 281 nm, 0.14, and -14.20 mV, 
respectively, with a smooth surface, mostly spherical shape, and high homogeneity 
(Figure 5.1B). 
Table 5.1  Characteristics of curcumin-loaded nanoparticles (CUR NP) coated with 
poly(vinyl alcohol) (PVA) and vitamin E poly(ethylene glycol) (MW = 5 kDa) (VP5k) 
and CUR NP re-dispersed from PVA CUR nanocomposite microparticles systems. 





polydispersity index (PDI), zeta (ζ) potential, CUR loading in NP, and encapsulation 















PVA CUR NP 181.3 ± 9.5 0.13 ± 0.03 -2.51 ± 0.92 13.00 ± 1.42 52.00 ± 5.70 
VP5k CUR NP 281.3 ± 15.9 0.14 ± 0.03 -14.20 ± 3.21 4.14 ± 1.20 16.57 ± 4.80 
Re-dispersed 
PVA CUR NP 
from nCmP  
(30:70, Fc = 
1.5%) 
251.9 ± 10.5 0.31 ± 0.07 -14.63 ± 0.50 N/A N/A 
Re-dispersed 
PVA CUR NP 
from nCmP  
(100:0, Fc = 
0.5%) 









Figure 5.1  Representative scanning electron micrographs of nanoparticles (NP) and 
nanocomposite microparticles (nCmP) systems. (A) poly(vinyl alcohol)-coated 
curcumin-loaded nanoparticles (PVA CUR NP), scale bar = 500 nm; (B) vitamin E 
poly(ethylene glycol) (MW = 5 kDa)-coated CUR-loaded nanoparticles (VP5k CUR 
NP), scale bar = 500 nm; (C) PVA-coated CUR-loaded nanocomposite microparticles 
with 30:70 NP to mannitol and 1.5% spray drying feed concentration (PVA CUR nCmP, 
30:70, Fc = 1.5%), scale bar = 1µm; and (D)  PVA-coated CUR-loaded nCmP with 
100% NP and 0.5% spray drying feeding concentration (PVA CUR nCmP, 100:0, Fc = 






5.3.2.2.  Drug loading and In Vitro Release from NP 
CUR was encapsulated in 3-hour Ac-Dex with an encapsulation efficiency of 
52% and 17% and CUR drug loading of 13 and 4 µg CUR/mg NP for PVA CUR NP 
and VP5k CUR NP, respectively (Table 5.1). The release profiles of CUR (Figure 5.2) 
indicate the sustained release of CUR, with burst release lower than 20% in all cases. 
At pH 7.4, CUR release reached a maximum (29%) after 24 hours for PVA CUR NP. 
Similarly, CUR released from VP5k CUR NP at neutral pH showed no significant 
increase after 24 hours, with a maximum release around 19%. CUR release in acidic 
buffer showed sustained release for both PVA and VP5k formulations, with 77% CUR 







Figure 5.2  In vitro curcumin (CUR) release profiles of nanoparticles and 
nanocomposite microparticles (nCmP) from poly(vinyl alcohol) (PVA) and vitamin E 
poly(ethylene glycol) (MW = 5 kDa) (VP5k)-coated particles in various pH conditions. 
(Top) Comparative release profiles of CUR release from PVA-coated CUR NP and 
CUR nCmP coated at pH 7.4 and pH 5.2. (Bottom) Comparative release profiles of CUR 






5.3.3.  Microparticle Characterization 
5.3.3.1.  nCmP Morphology, Size, Charge and Re-dispersion 
The morphology of the CUR nCmP formulations can be seen in Figure 5.1C 
and 1D for 30:70 and 100:0 NP to mannitol ratios, respectively. PVA CUR nCmP 
(100:0, Fc = 0.5%) showed wrinkled surface particles, forming raisin-like nCmP with 
visible NP, and a geometric diameter of 1.70 µm. PVA nCmP (30:70, Fc = 1.5%) 
showed some wrinkled particles and some spherical nCmP with a geometric diameter 
of 1.66 µm. NP re-dispersed from PVA nCmP exhibited an increase in size to around 
250 nm in both systems, with an increase in PDI (~0.3) (Table 5.1). The charge of 100:0 
nCmP remained similar to that of the parent PVA CUR NP, and the formulation with 
70% mannitol exhibited a more negative charge. The yields in the production of nCmP 
via spray drying were 52.6 and 54.3 % for PVA nCmP 30:70 and 100:0, respectively. 
 
5.3.3.2.  Drug loading and In Vitro Release from nCmP 
PVA CUR nCmP (30:70, Fc = 1.5%) had a drug loading of 1.06% (10.56 µg 
CUR/mg of nCmP) and PVA CUR nCmP (100:0, Fc = 0.5%) had a loading of 2.33%. 
The CUR nCmP formulations exhibited sustained release in both buffers, with 
prolonged release in acidic conditions. nCmP exhibited CUR burst release below 20%, 
and their release reached equilibrium at 32% by 24 hours at pH 7.4, and 96% and 71% 






5.3.4.  Water Content via Karl Fischer Titration  
The residual water content of PVA CUR nCmP formulations were below than 
3% (Table 5.2), as determined via colorimetric Karl Fischer Titration. 
Table 5.2  Characteristics of curcumin-loaded nanocomposite microparticles (CUR 
nCmP), including water content, CUR loading, nanoparticle (NP) loading in nCmP, NP 
loading efficacy in nCmP, geometric diameter (via Image J), tapped density, theoretical 
mass median aerodynamic diameter (MMADT), experimental MMAD (MMADE), and 














PVA CUR nCmP 
(30:70, Fc = 1.5%) 1.31 ± 0.13 10.56 ± 0.25 1.66 ± 0.73 0.4894 ± 0.02 
PVA CUR nCmP 
(100:0, Fc = 0.5%) 2.41 ± 0.59 23.33 ± 0.50 1.70 ± 0.67 0.3572 ± 0.03 
 
Particle System MMADT (µm) MMADE (µm) GSD (µm) 
PVA CUR nCmP 
(30:70, Fc = 1.5%) 1.16 ± 0.52 4.67 ± 0.05 2.11 ± 0.13 
PVA CUR nCmP 
(100:0, Fc = 0.5%) 1.02 ± 0.40 2.62 ± 0.24 3.48 ± 0.24 
 
5.3.5.  Solid-State Analysis of NP and nCmP 
The DSC thermograms of raw materials and nCmP are shown in Figure 5.3 
(Top). Raw CUR had an endothermic phase transition peak at 180°C. Raw 3-hour Ac-
Dex and PVA had no visible peaks, and raw VP5k had an endothermic peak at 58°C 





VP5k CUR NP presented a small endothermic peak at 58°C. PVA CUR NP and PVA 
CUR nCmP 100:0 had no visible peaks, while PVA CUR nCMP 30:70 had a broad 
endothermic peak at 159°C. Figure 5.3 (Bottom) presents powder X-ray diffractograms 
of raw materials and nCmP. Raw CUR and mannitol exhibited strong peaks, raw Ac-
Dex presented no peaks, and raw PVA and VP5k exhibited small peaks. The resulting 
PVA CUR NP and VP5k CUR NP formulations did not exhibit peaks respective to their 
constituents. After spray drying, PVA CUR nCmP (100:0) showed no peaks and PVA 








 Figure 5.3  (Top) Differential scanning calorimetry (DSC) thermograms and (Bottom) 
powder X-ray diffractograms (PXRD) of raw curcumin (Raw CUR), raw acetalated 
dextran following 3-hour reaction time (3-hour Ac-Dex), raw poly(vinyl alcohol) (Raw 
PVA), PVA nanoparticles (PVA CUR NP), raw vitamin E poly(ethylene glycol) (MW 
= 5 kDa) (Raw VP5k), VP5k nanoparticles (VP5k CUR NP), raw mannitol, PVA-coated 





and spray drying feed concentration of 1.5% (PVA CUR nCmP, 30:70, Fc = 1.5%), and 
PVA-coated CUR-loaded nCmP with 100% NP and spray drying feed concentration of 
1.5%  (PVA CUR nCmP, 100:0, Fc = 0.5%). 
 
5.3.6.  Density and Theoretical MMAD of nCmP 
The tapped density and the theoretical mass median aerodynamic diameter 
(MMADT) of PVA CUR nCmP are shown in Table 5.2. The corresponding values were 
0.49 g/cm3 and 1.16 µm for (30:70) and 0.36 g/cm3 and 1.02 µm for (100:0). 
 
5.3.7.  In Vitro Aerosol Performance of nCmP 
The in vitro aerosol dispersion of PVA CUR nCmP (Figure 5.4), evaluated in 
the NGITM, showed a broad dispersion of particles across all stages with 10% of the total 
mass deposition on the first stage for both formulations. For PVA CUR nCmP (30:70), 
66% of the particles deposited in stage 2 and stage 3, and only a 0.7% reached stage 7. 
In the case of PVA CUR nCmP (100:0), broader distribution of nCmP can be observed 
across stages 2 - 5. The experimental MMAD (MMADE) were 4.67 µm (GSD of 2.11 
µm) and 2.62 µm (GSD of 3.48) for 30:70 and 100:0 PVA CUR nCmP, respectively 
(Table 5.2). The increased MMADE value for the 30:70 formulation corresponds to the 
shift in nCmP to the lower stages of the NGI.  The FPF, RF, and ED were similar for 






Figure 5.4  In vitro aerosol dispersion performance of poly(vinyl alcohol)-coated, 
curcumin-loaded nanocomposite microparticles (PVA CUR nCmP) in a Next 
Generation ImpactorTM (NGITM) for Q = 60 L/min. (Top) Particle deposition on each 
stage of the NGI. (Bottom) Fine particle fraction (FPF), respirable fraction (RF). and 






5.3.8.  Artificial Mucus and Penetration Studies of Nanoparticles  
Images of the freeze-dried artificial mucus (Figure 5.5) indicate microporous 
interconnectivity and the penetration studies of free CUR, PVA-coated CUR NP and 
VP5k-coated CUR NP in AM are shown in Figure 5.6 (Top). Free CUR (in 5% DMSO) 
exhibited the slowest penetration through AM, and after 12 hours, a significant amount 
of CUR remained in the mucus, based on the yellow coloration of the AM. PVA CUR 
NP exhibited faster penetration through the AM in comparison to free CUR, but was 
also retained in the AM for the duration of the experiment. VP5k CUR NP exhibited the 
fastest penetration in mucus for the given samples. After 2 hours, a significant amount 
of VP5k NP were observed at the bottom of the Transwell®, which increased after 4 
hours. From 7-12 hours, the AM looked clearer as most of the NP reached and crossed 
the membrane of the Transwell®. Quantification of raw CUR and CUR penetration to 
the basolateral side of the Transwell® (Figure 6 (Bottom)) indicates that significantly 
more VP5k NP penetrated the AM in comparison to free CUR and PVA NP after 12 
hours.   
 
Figure 5.5  Representative scanning electron micrographs of freeze-dried artificial 







Figure 5.6  Evaluation of the mucus penetration capacities of free curcumin (CUR) 
containing 5% (v/v) DMSO, poly(vinyl alcohol) (PVA)-coated CUR NP, and vitamin 
E poly(ethylene glycol) (MW = 5 kDa) (VP5k)-coated CUR NP in artificial mucus 





in the apical side of the Transwell® at different time points. (Bottom) Fluorescence 
quantification of CUR collected in the basolateral side of the Transwell® at different 
time points and expressed as mass percent of NP. Statistical analysis was performed 
using ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which represents 
comparison among the groups) 
 
5.4.  Discussion 
Mucus is a complex fiber mesh responsible for trapping foreign agents in the 
lungs. The efficacy of treatments such as infections in CF mucus, lung tumors located 
beneath the mucus layer, or systemic treatment through pulmonary delivery is 
compromised by the ability of the therapeutic to escape mucosal entrapment and 
penetrate the mucus and/or epithelial layer beneath the mucus. In this project we 
evaluated and compared the penetration of a hydrophobic drug, CUR, with CUR-loaded 
NP coated with PVA or PEG (VP5k). It has been shown that PEGylation (MW 2 - 5 
kDa) prevents the mucin immobilization of NP, allowing for enhanced mucus 
penetration, and this phenomenon ceases to occur at higher PEG densities (>5 kDa) [26, 
35].  
This project involved the utilization of 3-hour Ac-Dex, which has a high cyclic 
acetal coverage and -OH conversion, as confirmed by 1H-NMR. We successfully 
conjugated vitamin E succinate with PEG 5k, as confirmed by 13C NMR, and fabricated 
3-hour Ac-Dex CUR NP coated with PVA or VP5k. As the synthesized Ac-Dex is 
highly hydrophobic, increased VP5k coating was required to stabilize the particles 





lyophilization steps, in contrast to previous work using 5-min Ac-Dex, with 5% less -
OH conversion and 24% lower CAC [30]. The high hydrophobicity of 3-hour Ac-Dex 
seemed to affect NP coating during fabrication more with VP5k than with PVA, 
suggesting that the polar groups (free -OH groups) in the polymer play an important 
role in the colloidal stability of NP [36] in coating with surfactants of higher molecular 
weight. 
The increased hydrophobicity of 3-hour Ac-Dex (in comparison to 5-min Ac-
Dex) resulted in a slower degradation rate and release of CUR, which was observed in 
the in vitro release study, where the release of CUR plateau after 24 hours at pH=7.4, 
corresponding to a normal pH in healthy tissue. In contrast, a sustained CUR release 
continued for 4 days in acidic conditions, reaching more than 88% release from NP and 
above 70% from nCmP, suggesting a release controlled mostly by erosion and 
degradation of the polymer. This selective release profile may be advantageous for the 
treatment of infectious diseases associated in CF patients with reduced pH airways [37] 
or cancerous tissue with solid tumors with pH ranging from 6.7 – 7.6, and lower within 
the cell  [38]. The low burst (<20%) seen in all formulations is another attribute of these 
particles that allowed for a controlled release profile. The slow degradation of 3-hour 
Ac-Dex can also prevent the release of drug before reaching the site of action, and this 
can easily be tuned by the time of reaction during the synthesis of the polymer. In 
addition, while drug loading was high in PVA coated NP, VP5k NP will require further 






VP5k-coated NP readily penetrated AM, with 33% increased penetration in 
comparison to PVA-coated NP and 80% in comparison to free CUR. The increased 
penetration is likely due to reduction in the muco-adhesion of NP to AM because of the 
PEG coating on the NP, and this is consistent to previously reported particle tracking 
analysis of PLGA-based VP5k NP [29]. PEGylation of NP via VP5k minimizes their 
interactions with mucin within the mucus mesh owing to its hydrophilic nature and 
nearly neutral charge. These characteristics allow the NP to escape steric hindrance and 
electrostatic interactions, allowing for successful mucus penetration, which can be 
beneficial for multiple applications in pulmonary delivery as well as other routes of 
delivery where mucus exists. While PVA-coated NP have traditionally been considered 
mucoadhesive when compared to PEGylated NP [39], and are known to decrease NP 
mobility when added to PEGylated NP [40], we observed that PVA-coated NP partially 
diffused through mucus escaping from the entanglement in mucin, likely due to its 
particle size (<200 nm) and molecular weight (13-23 KDa), which in another study was 
found to have similar mobility to 200 nm size PS-PEG-2k NP [41].  
Besides the mucosal barrier, the effective particle deposition is another 
challenge in pulmonary delivery. Factors affecting particle deposition include: (a) 
particle/droplet size (diameter), density, surface properties, shape (b) anatomy of the 
airways (c) ventilatory parameters [8]. In the design of dry powder formulations, the 
physical properties of the particle can be modulated. Particle size in pulmonary delivery 
is usually referred to the aerodynamic diameter, which will ultimately determine the 
deposition, and is dependent on the shape, density and geometric size of the particle. 





mechanism and escape the mucociliary clearance [42], these particle size range (2-3µm) 
also exhibit maximal phagocytosis and are rapidly eliminated by alveoli macrophages 
[43]. A successful deposition will require particles with a size in the range of targeted 
deposition in the airways that are small enough to escape clearance and big enough to 
avoid exhalation [44, 45]. 
To overcome this paradox, on this project we formulated nCmP comprised of 
nanoparticles agglomerated in the form of microparticles via spray drying, for a medium 
and deep lung deposition targets. Spray drying is a process that forces a fluid through a 
nozzle, producing a mist that generates amorphous and fine powders after drying [46]. 
The final product is determined and tuned based on the initial spray drying parameters 
and suspension characteristics such as viscosity (feed concentration) and 
nanoparticle/excipient mass ratio, among others [47]. 
The suspension containing with a 30:70 NP: mannitol ratio and feed 
concentration (Fc) of 1.5% produced nCmP with some hollow and mostly spherical 
morphology, compared to the ones spray dried with 100% NP and Fc of 0.5%, which 
showed a raisin-like morphology in its entirety. The image J evaluation of both nCmP 
showed a similar geometric diameter of both formulations (being 30:70 slightly 
smaller), however, their densities were different, being smaller for 100% NP ratio, due 
to its hollow shape. This last parameter finally defined the aerodynamic performance of 
the particle. As evaluated previously, particles with densities << 1 g/cm3 are 
characterized by hollow (or porous) morphology that increases the geometric diameter 
and decreases the aerodynamic diameter, enhancing the particle deposition in the lungs 





experimentally, the MMADE was significantly reduced (by 78%) compared to the 30:70 
nCmP formulation, as evaluated in the in vitro NGI. A higher ratio of NP to mannitol 
with a dilute feed concentration can lead to particles with deeper deposition in the lungs 
due to their hollow and wrinkled morphology [50]. nCmP aerosol performance can be 
tailored based on the selected parameters during the spray drying process. 
The increase in NP ratio did not affect the MMADT of the particles as much as 
the feed concentration in the formulation, however, the lack of mannitol seemed to 
increase the geometric standard deviation (GSD) in 100 %NP formulation, as observed 
in the NGI deposition figure. Mannitol is an excipient commonly used in DPI 
formulations, found to provide satisfactory aerosol performance and physical stability 
in spray dried particles [51], as in general the use of excipients, as carriers, facilitates 
the handling and dispersion of the cohesive micronized particles during inhalation [52].  
We observed that some agglomerations occurred during the simulated 
inhalation, as were evaluated by the slightly lower FPF observed in 100% NP 
formulation, which are opposite as we expected considering their deeper aerosol 
deposition.  Both formulations had a low content of water (<2.5%), which also favored 
the high ED and RF (≥ 90%) of particles during NGI evaluation.  
The different NP : mannitol ratio also allows the tunability for the development 
of specific drug loadings of the formulation. As expected, a high initial NP ratio will 
lead to a higher final DL.  
The particles produced by spray drying would likely dissolve the excipient 
(mannitol, if it has some) in the surface of the pulmonary airways, leaving behind loaded 





application. The nCmP formulated on this project re-dispered into nanoparticles upon 
contact to water, ensuring their nanoparticulate recovery, with slight increase in size and 
PDI, likely due to some agglomerations during the spray drying process. The recovery 
of NP from nCmP was also achieved because of the amorphization of raw materials, 
that in the case of 100% NP was complete (also due to the lack of mannitol), and for 
30:70, was highly enhanced, confirmed by the reduction of peaks, evaluated by PXRD.  
For the latest formulation, the peaks observed represent mannitol and no other raw 
material, and agrees with other studies where at high mannitol ratios, some of it can still 
form some crystals during spray drying [53].  
The thermal stability of nCmP was assessed using DSC, showing that nCmP that 
are highly stable under 120 °C in the case of PVA coated particles and under 55 °C for 
VP5k coated particles, which will likely influence in the storage recommendations of 
the product.  
Overall, VP5k-coated NP encapsulated in nCmP can enhance the penetration of 
NP into mucus and the nCmP formulation allow these NP to reach the site of action 
within the lungs. In particular, nCmP can be designed for specific lung depositions, 
which can provide a more personalized treatment of different pulmonary diseases. 
Additional studies to optimize the VP5k NP to enhance their encapsulation, efficacy 
studies in bacteria, and cytotoxicity studies are required for a better understanding of 






5.5.  Conclusions 
In this project we developed and evaluated the mucus penetration abilities of 
VP5k-coated NP encapsulated in nCmP for pulmonary delivery of a hydrophobic drug. 
The penetration of NP was enhanced using VP5k coating in comparison to PVA coating 
and free CUR. The 3-hour Ac-Dex system showed sustained release of the drug over 96 
hours with low burst release, reaching high release (~97%) in acidic conditions, which 
could be significant in the treatment of infections or tumors of acidic environments. The 
engineered nCmP were designed for tunable deposition of particles in the lungs, making 
them suitable for personalized treatment and targeted delivery of therapeutics via a 
pulmonary delivery of dry powder formulations.  
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CONCLUSIONS AND FUTURE WORK 
 
6.1.  Conclusions 
 
This dissertation focused on the development and characterization of 
nanoparticles and nanocomposite microparticles for pulmonary delivery applications, 
and the evaluation of their efficacy and penetration capabilities in representative in vitro 
platforms. 
Nanoparticles were successfully fabricated using the biodegradable polymer, 
acetalated dextran, by applying different synthesis techniques, encapsulating a variety 
of drugs, and utilizing different nanoparticle surface coatings for the formulation of 
nanotherapeutics with diverse purposes, and to obtain nanoparticles with sustained 
release and enhance hydrophobic drugs dispersion and stability. Nanoparticles were 
successfully encapsulated into nanocomposite microparticles via spray drying, showing 
tunability in properties, thereby allowing optimized deposition via pulmonary delivery. 
The chemopreventive properties of resveratrol were assessed using resveratrol-
loaded nanoparticles (RSV NP), showing its superiority when encapsulated in a 
nanocarrier. Evaluation of the nanoparticle formulation evaluation was performed using 
a 3D platform of lung cancer multicellular spheroids (MCS) which gives a better 
representation of solid tumors in vivo. It was found that were more effective at 





applications, which demonstrates the potential use of this formulation as a 
chemopreventive agent for lung cancer. 
For the potential treatment of lung cancer, paclitaxel (PTX), a strong 
chemotherapeutic, was encapsulated in dry powder aerosol nanocomposite 
microparticles (nCmP) via spray drying PTX-loaded nanoparticles in an aqueous 
suspention with mannitol. PTX nCmP showed excellent simulated deposition in the 
lungs, with deposition primarily being in the alveoli region, due to the optimized nCmP 
aerodynamic properties evaluated using a Next Generation Impactor. The efficacy of 
the formulation was found to be comparable to pure paclitaxel, and 3D MCS grown in 
an air interface culture conditions served as a model for the evaluation of the nCmP, as 
this model better mimics pulmonary conditions and serves as a bridge towards in vivo 
evaluations. Overall, the PTX nCmP system demonstrated the necessary characteristic 
for effective pulmonary deposition following aerosolization and cytotoxic effect in a 
variety of lung cancer cell culture models.  
In order to determine the potential for nanoparticles to overcome the mucus 
barrier in the lungs, PEGylated nanocomposite microparticles (nCmP) were created and 
their ability to penetrate mucus was evaluated. VP5k-coated nanoparticles (NP) were 
fabricated and encapsulated in nCmP via spray drying. VP5k NP successfully 
penetrated artificial mucus, thereby showing a promising option to overcome this 
limitation for multiple pulmonary diseases. Furthermore, the nanocomposite 
microparticles exhibited desirable targeted lung deposition and muco-inert properties 






6.2.  Future Work 
 
The work described in this dissertation involved the development and evaluation 
of nanoparticle-based formulations capable of overcoming current drug delivery 
obstacles. In addition, in vitro platforms were developed that can serve as models for 
the evaluation of dry powder formulations used for pulmonary delivery applications. 
Together, this work allowed for the development and evaluation of nanoparticle-based 
systems capable of: (i) preventing lung tumor spheroid formation, (ii) treating air-grown 
tumor spheroids following efficient in vitro aerosolization, and (iii) effectively 
penetrating mucus. These projects have the potential lead to further exploration and 
opportunities: 
• Development of tumor-penetrating nCmP by surface modifications of particles 
via attachment of tumor penetrating agents capable of reducing the diffusion 
and penetrations limitations of solid tumors. 
• Evaluation of the safety of VP5k-coated nanoparticles dissociated from nCmP 
using in vitro models and encapsulating VP5k NP with anti-bacterial drugs for 
efficacy evaluation of the formulation in the improvement of the treatment of 
bacterial infections seen in cystic fibrosis. 
• Development of an in vitro platform that combines bacteria and mucus for 
better evaluation of the efficacy of therapeutics against bacterial infections. 
• Exploration of other surface modification of nanoparticles, using targeting 
agents, charged and neutral coatings, for specific diseases, enhanced 













A.1. Experimental details 
A.1.1.  Materials  
Dextran from Leuconostic mesenteroides (MW: 9,000-11,000), pyridinium p-
toluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥99.9%), 2-
methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥99%), deuterium chloride (DCl, 
35 wt% in D2O, 99% atom D) solution, dichloromethane (DCM, > 99.8%), anhydrous 
sodium acetate, TritonTM X-100, bisBenzimide H 33342 trihydrochloride (Hoechst 
33342), methanol (HPLC grade, ≥ 99.9%) and acetic acid (≥ 99%) were obtained from 
Sigma-Aldrich (Natick, MA, USA).. Deuterium oxide (D2O, 99.8% atom D), polyvinyl 
alcohol (PVA, 88% hydrolysed, average MW 22000), and curcumin (CUR, >98%) were 
obtained from Acros Organics (Geel, Belgium). Formic acid (FA, ≥ 99.5%) and glycine 
(≥ 98.5%) were obtained from Fisher Scientific (Somerville, NJ, USA). Phosphate 
buffered saline 10X (PBS) was obtained from Research Products International (RPI) 
(Mount Prospect, IL, USA). Resveratrol (RSV, purity >98%) was purchased from 
AdipoGenTM (Sunnyvale, CA, USA). A549 human lung adenocarcinoma epithelial cells 
were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). 
Fetal bovine serum (FBS) was obtained from Atlanta Biologics (Flowery Branch, GA, 
USA). Collagen rat tail type I was obtained from Corning Inc. (Corning, NY, USA). 
Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L d-glucose and L-glutamine), 
Trypsine-EDTA (0.25%) phenol red, calcein AM, and ethidium homodimer-1 were 
obtained from Life TechnologiesTM (Carlsbad, CA, USA). Sodium pyruvate, penicillin 
streptomycin, and Fungizone were obtained from GE Health Life Sciences (Pittsburgh, 





from MP Biomedicals (Illkirch, France). Crystal violet in powder was obtained from 
Beantown Chemical (Hudson, NH, USA)  
 
A.1.2.  Synthesis of Acetalated Dextran (Ac-Dex)  
The synthesis of acetalated dextran (Ac-Dex) was conducted as previously 
described. Briefly, 1 g of lyophilized dextran (10k) and 25 mg of the catalyst PPTS were 
dissolved in 10 mL of anhydrous DMSO under pure N2 atmosphere. The reaction was 
initiated by the addition of 5 mL of 2-MOP and lasted for 5 minutes. The reaction was 
quenched with 1 mL of TEA. The schematic of the reaction is shown in Figure A.1. 
The product was then precipitated in basic water (distilled water with TEA, pH ~9), 
isolated via vacuum filtration, frozen overnight, and lyophilized (-50°C, 0.03 mBar) for 
48 hours to remove residual water. 
 
A.1.3.  Nuclear Magnetic Resonance (NMR) Analysis of Acetalated Dextran (Ac-
Dex)  
The total acetal coverage (conversion of hydroxyl groups) and type of acetals 
formed was determined by using 1H-NMR spectroscopy (Bruker 300 MHz NMR, MA, 
USA). In a NMR tube, 10 mg of Ac-Dex was suspended in 700 µL of D2O and then 
hydrolyzed with 30 µL of DCl. The hydrolysis of acyclic acetals produces methanol and 
acetone whereas cyclic acetals produce only acetone. The total acetal coverage and the 
cyclic acetal coverage (CAC) were determined after normalization of the methanol and 





the number of protons detected on each molecule. The results were expressed per 100 
molecules of glucose. 
 
A.1.4. Preparation of RSV-Loaded Ac-Dex Nanoparticles (RSV NP) 
Resveratrol-loaded nanoparticles (RSV NP) were prepared via single emulsion 
and solvent evaporation. 10 mg of RSV was dissolved in 1 mL of DMSO and 200 µL 
of the solution was added to 1800 µL of DCM. 1 mL of the RSV DCM solution was 
added to 49 mg of Ac-Dex (2 wt% initial loading), forming the organic phase. 6 mL of 
3% PVA in PBS (aqueous phase) was added to the organic phase and sonicated (Q500 
Sonicator, Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off pulse at an 
amplitude of 70% (100% amplitude = 120 µm). The resulting emulsion was transferred 
to a 40 mL spinning solution of 0.3% PVA in PBS and stirred for 4 hours to evaporate 
the organic solvent and stabilize the nanoparticles. The final solution was centrifuged at 
12,000 rpm (19,802 g.) and 4 °C for 20 minutes. The nanoparticles were washed twice 
with basic water, re-dispersed with 0.1% PVA in PBS, frozen overnight, and lyophilized 
(-50°C, 0.03 mBar) for 24 hours.  
The preparation of fluorescent NP, using curcumin (CUR) as a fluorescent 
additive, followed the same protocol mentioned above, adding 1 mg of CUR, and no 
resveratrol, to the organic phase. Blank NP were prepared similarly, excluding any 






A.1.5.  Particle Morphology and Shape Analysis via Scanning Electron 
Microscopy (SEM) 
The surface morphology and shape of the nanoparticles were evaluated by 
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning 
Electron Microscope (Germany). A suspension of 10 mg/ml of nanoparticles in basic 
water (pH 9) was dropped onto aluminum SEM stubs and dried at room temperature. 
The samples were sputter coated with a thin film of gold/palladium alloy a BIO-RAD 
system at 20 µA for 60 seconds under argon gas. Images were captured at 5 kV and at 
various magnifications. 
 
A.1.6.  Particle Size, Size Distribution, and Zeta Potential Analysis 
The size, size distribution (expressed by the polydispersity index, PDI), and zeta 
potential were measured by dynamic light scattering (DLS) using a Malvern Nano 
Zetasizer (Malvern Instruments, Worcestsershire, UK). The nanoparticles were 
suspended in basic water (0.5 mg/mL, pH 9), vortexed, and sonicated for one minute. 
All measurements were performed at 25°C. 
 
A.1.7.  Analysis of Nanoparticle Drug Loading 
Drug loading (DL) and encapsulation efficacy (EE) of RSV NP were determined 
via Ultra Performance Liquid Chromatography (UPLC, LaChrom, Hitachi, Japan). The 
detection of RSV was performed using an Ascentis column (C18, 5 µm x 150 mm x 4.6 





nm, temperature of 50°C, 20 uL per injection, 2-minute retention time, and a mobile 
phase containing 60% methanol and 40% aqueous formic acid (0.5 v/v %). RSV NP 
samples were completely dissolved (1 mg/mL) in the mobile phase prior to analysis. 
The RSV concentration was quantified by comparison with a standard calibration curve 
of RSV in the mobile phase. The drug loading and encapsulation efficacy were 












𝐦𝐚𝐬𝐬	𝐨𝐟	𝐑𝐒𝐕 + 	𝐦𝐚𝐬𝐬	𝐨𝐟	𝐀𝐜 − 𝐃𝐞𝐱 × 𝟏𝟎𝟎 
 
A.1.8. In Vitro Cell Studies 
A549 human epithelial adenocarcinoma cells were cultured in DMEM 
containing 10 v/v % FBS, 1 mM sodium pyruvate, 1 v/v % penicillin streptomycin (100 
U/ml penicillin, 100 µg/ml streptomycin), and 0.2 v/v % Fungizone (0.5 µg/ml 
amphotericin B, 0.41 µg/ml
 
sodium deoxycholate). Cells were incubated at saturated 





A.1.8.1.  RSV NP Cellular Uptake 
Confocal microscopy images were taken on A549 cells seeded on 35 mm glass 
bottom petri dish at a concentration of 500,000 cells/dish and incubated overnight. Cells 
were exposed to 100 µM CUR NP and incubated for 3 hours, washed 3X with PBS, 
stained with CellMaskTM deep red plasma membrane (0.5 µL/mL in PBS) and fixed 
with 4% paraformaldehyde in PBS. Images were taken at 100X magnification. For 
quantification, A549 cells were seeded at 5,000 cells/well in a flat-bottomed 96-well 
plate and allowed to attach for 24 hours. The cells were then exposed to 100 µM of NP 
containing CUR as the fluorescent probe, and were incubated for 3 hours at 37 °C. After 
exposure, the particle solution was removed, cells were washed twice with 200 mM 
glycine in PBS to remove any unbound particles, washed twice with cold PBS and 
finally fixed with 200 Proof ethanol for 10 min. For control cells, a similar protocol was 
followed with the exception that glycine was not necessary. The uptake was quantified 
using a fluorescence scan at 420/540 nm in the plate reader.  
 
A.1.8.2.  Two-Dimensional (2D) Cell Culture and Cell Viability 
The two-dimensional (2D) in vitro cytotoxic effect of RSV was evaluated in 
A549 cells using an acid phosphatase (AP) colorimetric assay. 5,000 cells/well were 
seeded into flat-bottomed 96-well plates and allowed to attach for 24 hours. Free RSV 
was dissolved in DMSO to facilitate solubility in media (final concentration 0.15 v/v % 
DMSO) and then the cells were exposed to different concentrations of free RSV (up to 





The acid phosphatase (AP) assay substrate contained 50 mM of pNPP in 1M 
sodium acetate (pH 5). Triton X-100 (final concentration 1 v/v % per well) was added 
to the substrate to permeabilize the membranes of the cells [1]. 20 µL of the substrate 
was added into each well (10 v/v % of total medium) and incubated for 2 hours. pNPP 
is hydrolyzed by the presence of AP in the cells and produces an intense yellow color 
(p-nitrophenolate) which was detected at a wavelength of 405 nm in a Citation3 
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The relative viability 
was calculated as the ratio of the fluorescence intensity of the sample (cells dosed with 
RSV) over the fluorescence intensity of control (cells only). 
A 2D viability test using blank nanoparticles was performed to evaluate the 
effect of different concentration of the particles in A549 cells. The concentrations 
ranged from 0.05 to 12 mg/ml and the protocol was followed as described above, with 
the difference that 20 µL of 20 mM resazurin was used for the test at 24, 48 and 72 
hours. The incubation time was 4 hours and the fluorescence intensity was detected at 
544/590 nm in the plate reader Cytation3 plate reader (BioTek Instruments Inc., 
Winooski, VT, USA).  
 
A.1.8.3.  Formation of 3D Multicellular Spheroids (MCS) 
A549 multicellular tumor spheroids (MCS), representing the three-dimensional 
(3D) cell culture platform, were formed via centrifugation to evaluate the in vitro effects 
of RSV formulations. Initially, three different cell concentrations (3,000, 5,000, and 





spheroid formation [2]) were seeded into ultralow attachment round-bottomed 96-well 
plates, centrifuged at 1100 g for 15 min, and incubated throughout the duration of the 
growth observation. Bright field images were taken at 0 hours, 4 hours, and 24 hours 
initially, and then every other day up to day 22 using a Citation3 Image reader (BioTek 
Instruments Inc., Winooski, VT, USA). The average size and morphology of the 
spheroids was evaluated over time.  
The characterization of the viability of the MCS was determined by a live/dead 
assay at day 1 and day 5 of MCS growth. The live/dead staining solution was prepared 
adding 40 µL of 1 mM ethidium homodimer-1 (red dye to detect dead cells), and 10 µL 
of 1 mM calcein AM (green dye for live cells) to 5 ml of PBS. Tumor spheroids were 
stained by gently removing 50 µL of media from the well and replaced by 50 µL of 
staining solution. The MCS were incubated at 37 °C, 5% CO2 for about 60 min before 
taking images with a Citation3 Image reader using Texas Red (red), GFP (green), and 
brightfield filters. 
 
A.1.8.4.  Growth Inhibition of MCS 
The growth inhibition of A549 MCS was evaluated in two types of studies 
(prevention or treatment) with free RSV and RSV-loaded nanoparticles (RSV NP). For 
prevention studies, the MCS were dosed on the same day as the cells were seeded, after 
centrifugation of the plates. The dosage with RSV included concentrations of 25, 50, 
100, 250 and 500 µM for free and NP formulations. For treatment studies, MCS were 





and 500 µM. In both prevention and treatment studies, the plates were incubated at 
standard conditions to allow growth and were imaged periodically (bright field). The 
growth or inhibition of MCS upon RSV exposure was analyzed by calculating the 
change in size relative to untreated controls.  
 
A.1.8.5.  Clonogenic assay 
A clonogenic assay was performed on MCS dosed with free RSV after 
prevention and treatment studies to test the ability of cells to recover and form colonies. 
On day 15, MCS were transferred to another plate, washed twice with PBS, trypsinized 
to dissociate the MCS for 5 min and pipetted in and out to break any remaining clusters. 
Cells were seeded in 6-well plates at a concentration of 500 cells/well and incubated for 
14 days. At the end of the period of incubation, media was gently removed from the 
wells, colonies washed once with PBS and fixed with methanol: acetic acid (3:1) for 20 
minutes. After removing the fixing solution, colonies were stained with 0.5 % (w/v) 
crystal violet in distilled water for 45 minutes. Finally, the wells were washed with 
distilled water, dried under the hood and the colonies counted.  
 
A.1.9. Statistical Analysis 
 The measurements were performed in at least triplicate. All values were 
presented as mean ± standard deviation.  The half maximal inhibitory concentration 
(IC50) values were calculated using a polynomial regression in PRISM version 5.0 









Figure A. 1  Chemical structures of trans-resveratrol (top) and synthesis of acetalated 









Figure A. 2  Cell viability analysis of A549 cells measured using an acid phosphatase 
assay after dosing with free resveratrol (RSV) grown using the following conditions and 
times: (A) 2D monolayer after 48 hours, (B) 2D monolayer after 72 hours, and (C) 3D 









Table A. 1  Clonogenic assay data representing the number of colonies, plating 
efficiency (%), and survival fraction (%) of A549 cells from multicellular spheroids 
exposed to free resveratrol (RSV) in prevention and treatment studies. Data is presented 
as number of colonies compared with untreated control (mean ± standard deviation, n = 
3). Statistical analysis was performed using Student’s t-test (* p < 0.05, ** p < 0.01, *** 











Control 78 ± 2.3 15.6 ±  0.5 100.0 ±  3.4 - 
Control-D 53 ± 4.4 10.6 ±  0.9 67.9 ±  5.6 0.002 
25 µM 60 ±  7.9 12 ±  1.6 76.9 ±  10.2 0.048 
100 µM 57.3 ±  3.2 11.5 ±  0.6 73.5 ±  4.1 0.001 
250 µM 30.3 ±  4.9 6.1 ±  1.0 38.9 ±  6.3 0.001 











Control 79 ± 10 15.7 ± 1.9 100.0 ± 12.2 - 





25 µM 83 ± 2 16.7 ± 0.4 105.9 ± 2.6 0.491 
100 µM 83 ± 10 16.5 ± 1.9 105.1 ± 12.3 0.639 
250 µM 75 ± 6 15.1 ± 1.1 95.8 ± 7.0 0.636 
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Figure B. 1  Chemical structures of (A) curcumin (CUR) and (B) synthesis of acetalated 
dextran (Ac-Dex) from parent dextran in dimethyl sulfoxide (DMSP) with the catalyst 








Figure B. 2  Nuclear magnetic resonance (NMR) confirmation of the reaction of vitamin 
E succinate and m-poly(ethylene glycol) (PEG) with a molecular weight of 5 kDa to 
produce vitamin E PEG (VP5k). (A) Schematic and conditions of the reaction and (B) 
13C NMR spectrums. 
